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INTRODUCTION 
Nogalamycin and Its Analogs: History and Chemistry 
Nogalamycin (1), an anthracycline antibiotic produced by 
Streptomyces nogalater,^'^ was isolated 20 years ago at The 
Upjohn Company.^ It exhibits inhibitory activity against a 
variety of gram-positive bacteria in vitro and several 
tumors in vivo. 
During the period of interest in nogalamycin, structural 
studies were continued and the analogs obtained were tested 
for biological activity. At the early stage of the 
investigation, the gross structure of nogalamycin was 
established based on chemical studies and spectral 
analyses.However, there were some uncertainties 
regarding the absolute stereochemistry of the amino sugar 
and absolute stereochemistry at C-7, C-9, and C-10 of 
nogalamycin. Arora later carried out a crystallographic 
study of nogalamycin and established the absolute 
stereochemistry and complete structure of the compound 
(Figure 1). In addition to revealing the molecular 
structure, he also proposed models for the probable mode of 
interaction with DNA. 
In the course of investigating the antitumor activity of 
nogalamycin, a large number of nogalamycin analogs have been 
prepared from the degradation of nogalamycin/* Almost all 
of these can be included in two series: the nogalarol 
2 
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CH,' 
COOCH, 
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CH,0 
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1 
Figure 1. Nogalamycin 
series and the nogarol series. The difference between the 
two is the presence of the carbomethoxyl group at C-10 in 
the nogalarol series and its absence in the nogarol series. 
Scheme I and Scheme II summarize the preparation, structure 
and nomenclature of the major nogalamycin analogs. 
Dehydration of nogalamycin with triethylamine in 
refluxing methanol gave nogalarene (2). At room 
temperature, nogalamycin was hydrolyzed in 0.5 N potassium 
hydroxide to dis-nogalamycinic acid (3). The unionized form 
of acid 3 is indicated, but it exists as the zwitterion. 
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The acid 3 is readily decarboxylated upon dissolving in DMF 
to give dis-nogamycin (7). Acidic methanolysis of 
nogalamycin (1) resulted a pair of 7-con- and 
7-dis-O-methylnogalarols (4, 5). Similarly, dis-nogamycin 
gave 7-con- and 7-dis-O-methylnogarols (9, 10) when treated 
with acidic methanol. The ratio of compounds 9 and 10 
formed in the reaction was 4:6. Separation of 9 and 10 was 
quite difficult, as aromatization of ring A occurred readily 
to form nogarene (8), which was prepared independently by 
heating dis-nogamycin in aqueous acid. Catalytic 
hydrogénation of nogalamycin and dis-nogamycin replaced the 
nogalose at C-7 by hydrogen to form 7-deoxnogalarol (6) and 
7-deoxynogarol (11) f respectively. 
The isomerization of various anthracyclines at C-7 by 
reaction with trifluoroacetic acid followed by hydrolysis 
p 
has been reported. Dis-nogamycin was found to give a 
somewhat similar reaction. It reacted with trifluoroacetic 
acid under mild condition to replace the nogalose moiety. 
The resulting intermediate was not characterized but reacted 
with nucleophiles to introduce the nucleophile at C-7 with 
Q 
essentially complete stereospecificity. The products had 
the opposite chirality at C-7 to that of dis-nogamycin. The 
reaction in which the nucleophile was methoxide is indicated 
in Scheme III. 
6 
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The reaction shown in Scheme III appears to be entirely 
general for alkoxides, mercaptides, acid anions, ammonia, 
primary and secondary amines, azides, and carbanions. The 
product in all cases was the con isomer. It is interesting 
to find that 7-con-O-methylnogarol reacted with 
trifluoroacetic acid to give a product which subsequently 
reacted with sodium ethoxide to form 7-con-O-ethylnogarol. 
This suggests that the overall reaction always results in a 
con product regardless of chirality at C-7 in the initial 
reactant. 
The nature of the product obtained in the first step is 
somewhat uncertain, as purification difficulties prevented 
its characterization. It seems probable that during the 
course of the reaction a trifluoroacetate is formed at C-7, 
7 
and this intermediate is attacked by the nucleophlle (Scheme 
IV). In order to produce the observed chlrallty, the 
Scheme iv 
hydroxyl group at C-9 must influence the stereochemistry of 
the intermediate via an oxetane ring or its ion pair 
equivalent. Only ring A is indicated in Scheme IV. This 
procedure allowed the preparation of a large number of 
nogalamycin analogs in which only con isomers could be 
obtained. 
Antitumor Activity of Nogalamycin and Its Analogs 
About 60 analogs of nogalamycin have been prepared, and 
most of them showed considerable activity as antitumor 
agents. Of all the nogalamycin analogs, 7-con-O-methyl-
nogarol (10) has been found to be superior to its parent 
CF3COOH 
OR 
CF3OO Nu 
compound in tests of its antitumor activity. 9-14 
8 
The in vitro L-1210 leukemia growth inhibitory activity 
and the in vivo antitumor activity of analogs of several 
structural types are shown in Table 1. There was some 
correlation between the in vitro and in vivo activity. 
Analogs with high IDgg values were not very active in vivo; 
however, a low IDgg value (<0.2 yM), did not necessarily 
indicate high in vivo activity. 
The most active compounds against P-388 leukemia were, 
in decreasing order, 7-con-O-methylnogarol, dis-nogamycin, 
7-con-O-methylnogalarol, 7-dis-O-methylnogarol, 7-con-O-
ethylnogarol, and 7-dis-O-methylnogalarol. Against the B-16 
melanoma the most active compounds were 7-con-O-methyl-
nogarol, dis-nogamycin, 7-dis-O-methylnogarol, nogalamycin, 
and 7-dis-O-methylnogalarol. Thus, except for dis-
nogamycin, the most active analogs did not contain the 
nogalose moiety. 
The 7-deoxy compounds, 7-deoxynogalarol and 
7-deoxynogarol, were only marginally active against P-388 
leukemia and the optimum doses were high (50-100 mg kg"^) 
compared to the other analogs. Neither of the aromatized 
analogs (nogalarene and nogarene) showed much activity 
against P-388 leukemia. 
Dis-nogamycin was more active than con-nogamycin against 
both P-388 leukemia and B-16 melanoma. However, 7-con-O-
methylnogarol and 7-con-O-methylnogalarol were considerably 
Table 1. In vitro and in vivo antitumor activity of 
nogalamycin and its analogs 
L-1210 
leukemia 
vitro P-388 L-1210 B-16 
ID*50 leukemia leukemia melanoma 
Compound (UM) ILS ILS ILS 
Nogalamycin 0.078 49 38 72-157 
Dis-nogalamycin acid 1.00 56 18 NT 
Dis-nogalarol 0.89 0 0 NT 
7-Dis-Ô-methylnogalarol 0.27 60 12 84 
7-Con-O-methylnogalarol 0.13 98(l/6)b NT 35 
7-Deoxynogalarol 0.58 27 4 NT 
Nogalarene 0.24 50 2 NT 
Dis-nogamycin 0.18 93 27 61-260 
Con-nogamycin 0.56 44 NT 28 
7-Dis-O-methylnogarol 0.41 76 NT 105 
7-Con-O-methylnogarol 0.061 197(3/6) 140(1/6) 60-114 
7-Dis-O-ethylnogarol 0.43 NT° NT 34 
7-Con-O-ethylnogarol 0.16 63 NT 25 
7-Deoxynogarol 0.94 21 NT NT 
Nogarene 0.22 17 NT NT 
®IDgQ = Concentrations required for 50% inhibition. 
^Numbers in parentheses = Number of cures/total Number 
treated. 
°NT = Not tested. 
10 
more active than their corresponding 7-dis isomers against 
P-388 leukemia. Against B-16 melanoma, no difference was 
apparent between 7-con- and 7-dis-O-methylnogarol; 7-con-
0-methylnogalarol was less active than 7-dis-O-methyl-
nogalarol. 
Of the analogs, 7-con-O-methylnogarol and dis-nogamycin 
were considered the best compounds for further investiga­
tion. Despite strong activity against P-388 leukemia and 
B-16 melanoma, dis-nogamycin was only marginally active 
against L-1210 leukemia and was inactive when tested further 
in the colon 26, colon 38 and 008?^ mammary tumors, and in 
the Lewis lung carcinoma. 7-Con-O-methylnogarol has a 
rather broad spectrum of activity in mouse tumors. In 
addition to activity in the P-388 and L-1210 leukemias and 
in B-16 melanoma, 7-con-O-methylnogarol was significantly 
active against the murine colon 26 and colon 38 tumors, as 
well as the CDSF^ mammary tumor. It was not considered 
effective against Lewis lung carcinoma, although 38% ILS 
value was achieved in the experiment (40% ILS is the 
criterion of activity). 
Adriamycin (12) has been one of the major drugs for 
cancer treatment in the past decade. However, the success 
of adriamycin is limited by its cumulative cardio-
toxicity.The largest amount of adriamycin which 
11 
OH 
OH 
OH 
CH3O O OH 0-Sugar 
IZ 
can be given to a patient is about 500 mgm~^ of body surface 
without danger of irreversible, fatal cardiotoxicity. Two 
1 7 
adriamycin analogs currently in clinical trials are also 
known to induce rubidazone, which has been reported to be 
cardiotoxic in humans at cumulative doses of greater than 
1500 mgm~^. As the consequence of this cardiotoxicity 
property of adriamycin and its analogs, any new anthra-
cycline analog proposed for clinical use must be evaluated 
for its cardiotoxic potential. 7-Con-O-methylnogarol is of 
no exception, and the compound was investigated by the 
18 
standard procedures using rabbits as the testing animal. 
All adriamycin-treated control rabbits died of drug-
induced cardiomyopathy and congestive heart failure at 222 
to 277 mgm"^. No 7-con-O-methylnogarol-treated rabbits died 
from cardiotoxicity at doses up to 3700 mgm"^, thus 
7-con-O-methylnogarol is at least 15 times less potent than 
12 
is adriamycin in inducing cardiotoxicity, and the compound 
could possess a therapeutic advantage over adriamycin. 
The Molecular Basis of Antitumor Activity 
To understand the mechanistic aspects of the antitumor 
activity of the antitumor nogalamycin analogs, the molecular 
basis of antibiotic action of anthracyclines has been 
extensively studied. The anthracyclines form complexes with 
deoxyribonucleic acid (DNA) with stability constants in the 
range of 10^ to 10® M*"^. Because the main biochemical 
effects of the antitumor anthracyclines are concerned with 
nucleic acid synthesis and function, this type of molecular 
association has been studied in detail. On the basis of the 
physicochemical properties of the complex, including changes 
in the spectroscopic and polarographic properties of the 
19 
antibiotic induced by native DNA, as well as changes in 
DNA sedimentation rate, viscosity, or denaturation profile 
19 20 induced by the antibiotics, ' an intercalative mode of 
association was proposed. 
The intercalation complex is a type of non covalent 
binding of small molecules to double-helical DNA, originally 
21 
suggested by Lerman for explaining the molecular 
association of acridine dyes and DNA, and subsequently 
accepted as the mode of interaction of a wide range of 
22 different drugs with a DNA receptor. According to the 
model, a planar molecule is intercalated between two 
13 
adjacent base pairs of the biopolymer, the distance between 
the same base pairs become 6.8 in order to allow normal 
Van der Waals contact with the intercalating molecule. In 
anthracyclines, stabilization of the complex was ascribed to 
several factors. Because of the close contact of the 
electron-deficient quinone chromophore with the electron-
rich purine and pyrimidine bases, insured by the intercala­
tion, the conditions for the formation of a DNA complex 
should be fulfilled. Such an electron donor-acceptor 
complex is typical of the quinones. 
Different methods for the study of the DNA complexation 
reaction were employed in the early investigations. The 
interaction of the anthracycline with DNA can be monitored 
spectrophotometrically or by equilibrium dialysis.^3 a 
fluorometric method based on the quenching of the typical 
anthracycline fluorescence by DNA has also been developed.^ 4 
Other useful information can be obtained by circular 
O C 9 g O *7 
dichroism spectroscopy, ' calorimetric measurements, 
thermal denaturation of DNA, and viscosimetric determina-
23 tions. An additional promising technique for the study of 
anthracycline interactions with biological macromolecules or 
with metal ions is offered by Raman spectroscopy.^® 
A direct consequence of DNA complexation is the 
inhibition exerted by anthracyclines on the template 
activity of DNA in vitro. The detailed mechanism of this 
14 
inhibition remains to be established: both prevention of 
separation of the DNA strands and hindrance to the 
attachment of the polymerase due to distortion of the DNA 
structure have been proposed as possible causes.^2 
Taking account of the DNA intercalation model as the 
most widely accepted candidate for the representation of the 
main drug-receptor complex, a number of structural and 
configurational features of the anthracyclines have to be 
considered as necessary conditions for complex formation 
and, therefore, for the exhibition of biological activity. 
Among these, the planar, electron-withdrawing quinone 
chromophore should be taken as an obvious requirement. The 
relationship between the ability to form intercalation 
complexes and the pharmacological activities is not clear, 
because of the different biological effects of the 
intercalating agent.^9 
Nogalamycin interacts with DNA by intercalation of the 
chromophore between adjacent base pairs of the helix. 
The formation of the intercalation complex was shown by the 
36 
reversal of supercoiling in supercoiled DNA, an increase 
on 
in Tm of DNA and in the viscosity of DNA solution. 
Further evidence for the intercalation complex formation was 
shown by a decrease in the sedimentation coefficient of DNA 
and removal of kinks from T7 DNA in the presence of 
37 
nogalamycin. Dichroism studies had shown that the plane 
15 
of the nogalamycin chromophore is perpendicular to the helix 
axis when the antibiotic is bound to DNA, and nogalamycin 
cannot be reduced polarographically when it forms a complex 
with DNA. Competitive fluorescence polarization using DNAs 
of differing base composition indicated that nogalamycin 
analogs containing the nogalose moiety generally prefer 
*38 
adenine and thymine. 
To further study the biological properties of the 
nogalamycin analogs, their effect on macromolecular 
synthesis and DNA binding was investigated in L-1210 
leukemia cells.Nogalamycin strongly inhibits RNA 
synthesis, and to a somewhat lesser degree, DNA synthesis. 
The results with 7-con-O-methylnogarol (Table 2) against DNA 
and RNA synthesis in L-1210 cells were quite surprising. It 
almost totally failed to inhibit either RNA or DNA 
synthesis. The dis isomer was much less active than 
nogalamycin in the inhibition of both RNA and DNA synthesis. 
In the case of the other two pairs of con and dis isomers, 
the con was much less active than was the dis. 
The interaction of calf thymus DNA with nogalamycin and 
its analogs was measured by circular dichroism (CD) and by 
Tm determination (Table 3). The difference between CD 
curves at 465 nm of DNA and of the compound taken separately 
and the CD curve of the mixture was determined and expressed 
as millidegrees of ellipticity. The values shown are 
16 
Table 2. Inhibition of macromolecular synthesis by 
nogalamycin and its analogs 
ID50 (nmol/ml) 
Compound DNA RNA 
Nogalamycin 3.3 0.4 
Dis-Nogalamycinic acid 15 3.6 
Dis-Nogamycin 3 0.5 
7-Dis-O-Methylnogalarol 3.8 0.5 
7-Con-O-Methylnogalarol 7-17 0.5 
7-Dis-O-Methylnogarol 11.6 7.8 
7-Con-O-Methylnogarol 37.2 46 
7-Dis-O-Ethylnogarol 3.2 0.8 
7-Con-O-Ethylnogarol 10.6 5.2 
Table 3. Interaction between DNA and nogalamycin and its 
analogs 
Compound 
CD (millidegrees 
of ellipticity) ATm CO 
Nogalamycin 12 15.0 
Dis-Nogalamycinic acid 8 4.4 
Dis-Nogamycin 11 11.7 
7-Dis-O-Methylnogalarol 8 5.0 
7-Con-O-Methylnogalarol 6 3.1 
7-Dis-O-Methylnogarol 8 4.0 
7-Con-O-Methylnogarol 2 0 
7-Dis-O-Ethylnogarol 8 3.9 
7-Con-O-Ethylnogarol 2 -2.5 
17 
proportional to drug-DNA interaction. The results indicate 
that nogalamycin and dis-nogalamycin had a much stronger 
binding affinity to calf thymus DNA than did dis-nogala-
mycinic acid, and the two compounds in the con-nogarol 
series interacted much less strongly in the dis series. The 
binding effect in the nogarol series (con vs. dis) was much 
less pronounced. 
7-Con-O-methylnogarol was the most cytotoxic analog 
tested, and it was also found to be the most active analog 
against both P-388 and L-1210 leukemia.This analog, 
surprisingly, neither interacted strongly with DNA nor 
markedly inhibited DNA and RNA synthesis. These results 
collectively suggest that the biological activities of 
7-con-O-methylnogarol is probably mediated through some 
mechanism other than the interaction with DNA, the mechanism 
suggested to explain antitumor activities for most anthra-
2Q 
cycline antibiotics. Because of the superior biological 
activity and the unique biochemical characteristics of 
7-con-O-methylnogarol, further investigation on the 
properties is proceeding. 
18 
LITERATURE SURVEY 
Nogalamycln and its analogs are structurally different 
from the classical anthracyclines in that the amino sugar 
residue is joined to the aromatic D-ring via both glycoside 
and C-C bonds forming a benzoxocin ring system. Additional 
examples of anthracyclines containing this structural 
feature, namely, arugomycin (13a) and decilorubicin (13b), 
have been reported recently 
OH 
OH 
Sugar-O 
HO O OH 0-Sugar 
laa Arugomycin 
Sugar-O 
O OH 0-Sugar 
lab Decilorubicin 
Nogalamycin and its analogs have been the subject of 
interest in recent years because of their potential 
19 
therapeutic value in cancer chemotherapy. Of all the 
analogs, 7-con-O-methylnogarol has the most outstanding 
antitumor properties. Its biochemical properties differ 
greatly from those of the other anthracyclines. The fact 
that 7-con-O-methylnogarol is a likely clinically-effective 
chemotherapeutic agent, coupled with the remarkable 
structure of the analog (presence of benzoxocin ring 
system), make it an interesting and challenging synthetic 
target for our group. In order to supply a framework of 
reference for the discussion presented in the latter 
sections of this thesis, a brief review of the previous 
synthetic attempts on nogalamycin analogs is given below. 
DeShong and Leginus*^ have synthesized benzoxocin 17, a 
model system of the glycosidic portion of 7-con-O-methyl-
nogarol. The key step in the reaction sequence involved the 
cycloaddition of nitrone 14 with vinyltrimethylsilane to 
produce isoxazolidines 15, followed by fluoride-induced 
fragmentation of 15 to give unsaturated aldehyde 16. 
Catalytic hydrogénation of 16 and subsequent mild acid 
hydrolysis furnished the benzoxocin 17. The overall 
transformations are summarized in Scheme V. 
Hauser and Adams^^ developed a methodology to construct 
a more highly functionalized benzoxocin ring system, which 
is shown in Scheme VI. For both paths a and b, the 
aldehydofuranose 18 served as a chiral synthon for 
20 
Scheme v 
Me O' 
Me 
" .O 
>—Ph jff^^SIMea HF_ 6 fg+ H Me— 
SIMes lA 15 
Me 
"f )-
fr 
Ph 1Ha.Pd/C 
2H* 
IS 12 
OBn 
Ar = 
OBn 
Scheme VI 
BnoX y% c:v 
13. 
OHC 
18 \ 
OH OH 
21 CHa 
OBn Q ?» %"=0H 
24 CHa 
21 
constructing the optically active benzoxocins 21 and 24. In 
path Si, reaction of methyl ketone 19 with the Grignard 
reagent formed from the benzyl ether derivative of 
2-bromo-4-methyl phenol, followed by careful hydrogénation 
gave debenzylated product 20. However, attempted hydrolysis 
of 20 and rearrangement to benzoxocin 21 only produced a 
complex mixture. 
In path b, reaction of ketone 22 with methyllithium, 
followed by hydrogenolysis gave alcohol 23. In contrast to 
the unsuccessful conversion of intermediate 20 to oxocin 21, 
the transformation of 23 to the corresponding oxocin 24 with 
L-ido configuration proceeded smoothly and with high 
stereoselectivity. 
44 Hauser et al. also prepared the racemic ketobenzoxocin 
28, which can be converted to racemic sugar analogues. The 
transformation to 28 is shown in Scheme VII. 
Fries rearrangement of ester 25, followed by reacted 
with excess of methyl lithium furnished the tertiary alcohol 
27. Treatment of 27 with bromine in methanol, and 
subsequent acid hydrolysis in acetic acid containing a trace 
of sulfuric acid gave the rigid bicyclic benzoxocin 28 in 
good yield. Other sugar analogues with the manno-, talo-, 
altro- and galacto- configurations can be derived from the 
resulting benzoxocin 28. 
22 
Scheme vil 
o 
CH30H 
1 Br2.CH30H 
Bates and Sammes^^ reported a flexible method for the 
construction of a benzoxocin ring which is exemplified by 
the preparation of the DBF ring system of nogalamycin 
(Scheme VIII). Reaction of acetophenone 29 with 
2-furyl-lithium gave the alcohol 30. The resulting adduct 
30 was oxidized with m-chloroperoxybenzoic acid to yield 
diastereomeric pyranuloses 31. Methylation of 31 with 
methyl iodide-silver oxide afforded two methyl acetals. 
Epoxidation of the major diastereomer with t-butylhydro-
peroxide, followed by reduction with sodium borohydride 
produced epoxy-alcohol 32 as the only product. Treatment of 
32 with dimethylamine gave amino alcohol 33, and the 
23 
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resulting nucleophilic addition was regio- and stereo-
specific. Selective debenzylation and demethylation, 
followed by cyclization to produce benzoxocin 34 was 
achieved by treatment of 33 with trimethylsilyl iodide and 
trimethylsilyl chloride. 
Joyce et al.^® foresaw a strategy involving an important 
intermediate ketone 40/ which bears three of the chiral 
24 
centers of nogalamycin (C-2', 3', 4'). That intermediate 
has the key components of the benzoxocin portion of 
nogalamycin analogs. 
The approach to ketone 40 centered on an intramolecular 
N-sulfinyl dienophile Diels-Alder cycloaddition (Scheme IX). 
Treatment of carbamate 35 with thionyl chloride/pyridine and 
Scheme IX 
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catalytic amount of copper(II) chloride produced a reactive 
N-sulfinyl carbamate 36, which cyclized to give bicyclic 
dihydrothiazine oxide 37. Oxidation of 37 with 
trifluoroperacetic acid provided epoxysultam 38 with high 
selectivity. Transformation of 38 into ether 39 was 
achieved via three steps. Cleavage of the double bond of 39 
with ruthenium tetroxide yielded ketone 40, which will be 
used in approaches to nogalamycin. 
Vatele*^ proposed an interesting strategy towards the 
bfenzoxocin ring system of nogalamycin analogs. The strategy 
involves stereospecific formation of the quaternary center 
at C-5' by a Claisen rearrangement and construction of D 
ring by a Diels-Alder reaction (Scheme X). 
Precursor 41 was prepared from D-glucose via several 
steps. Reaction between alcohol 41 and the sulfoxide 
derivative 42, in the presence of potassium hydride, gave 
smoothly the o-g-unsaturated ester 43 in moderate yield with 
exclusive formation of the Z-isomer. This novel step 
involved a Michael addition of alkoxide, derived from 
alcohol 41, to the unsaturated sulfoxide 42 with elimination 
of fluoride anion. The resulting adduct then underwent 
Claisen rearrangement, followed by sulfoxide elimination in 
situ to give ester 43. This step demonstrates a unique 
formation of the quaternary center by Claisen rearrangement 
stereospecifically. 
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In order to investigate the possibility of constructing 
ring D of nogalamycin by a Diels-Alder reaction, a model 
diene 45 was made from ester 44. Surprisingly, Diels-Alder 
reaction between 45 and 2-bromo-5-metl)oxy-l, 4-naphthoquinone 
(46) did not proceed even in boiling toluene. In the 
presence of boron trifluoride-etherate, no cycloadduct was 
formed, but instead aldehyde 47 and hydroquinone 48 were 
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Isolated. Because of the unsuccessful Diels-Alder reaction 
in the model system, the investigation was terminated. 
Smith^® reported a different approach towards the 
synthesis of benzoxocin ring system. Their approach 
involved the synthesis of a suitable amino sugar and a 
D-ring synthon, followed by stereoselective glycosidation of 
the D-ring synthon with the amino sugar, and finally 
adjustment of the functionality of the resulting adduct to 
allow C-C bond formation between C-2 and C-5' (Scheme XI). 
Scheme XI 
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Glycosidation of phenol 49 with the sugar 50 could be 
achieved under SnCl^-catalyzed conditions. 
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Functlonalization of the adduct 51 gave enol ether 5 2 ,  which 
was subjected to cyclization. In order to achieve the 
cyclization, it is necessary to develop a positive charge at 
C-5' of the vinyl ether 52, which will then react with the 
electron rich aromatic ring. In practice, a proton source 
like trifluoroacetic acid, or a positive halogen species 
like N-bromosuccinimide, or iodonium dicollidine 
perchlorate, was tried. Each of the above reagents could 
generate the positive charge at C-5'; however, none afforded 
the required cyclization product. 
Kawasaki et al.*^ accomplished a total synthesis of 
(+)-nogarene (8) by a convergent approach. The key step in 
the synthesis involved a regioselective Diels-Alder reaction 
of quinone 54 with diene 55 at room temperature. The 
resulting cycloadduct was treated with DDQ to give quinone 
56, which underwent acid hydrolysis to complete the total 
synthesis (Scheme XII). 
Scheme XII 
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RESULTS AND DISCUSSION 
Retrosynthetic Analysis and General Strategy 
7-Con-O-methylnogarol (10), an analog of the antibiotic 
nogalamycin, has been found to exhibit superior antitumor 
13 
activity to its parent compound. Since 7-con-O-methyl-
nogarol is a potentially effective chemotherapeutic agent 
with remarkable structural features, we initiated a 
I 9" 
HO O OH OCH3 
in 
a synthetic effort toward that molecule and the 
corresponding analogs. The most noticeable feature of the 
target molecule which differs from the normal anthra-
cyclines, is the presence of a benzoxocin ring system. The 
benzoxocin ring contains an amino sugar residue joined to 
the aromatic D ring. Different synthetic approaches toward 
this interesting ring system have been reviewed in the 
previous section, but most of them cannot be elaborated to 
the total synthesis of nogalamycin. The only successful 
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total synthesis of a nogalamycin analog (nogarene), which 
exhibits no significant biological activity, was completed 
49 by Kawasaki et al. 
In the course of our investigation, we devised an 
efficient route to 7-con-O-methylnogarol. The approach is 
threefold: (1) preparation of the ketone 58 with three 
contiguous stereogenic centers which could be converted into 
C-2', 3', 4' of the target molecule; (2) synthesis of a 
suitable tetracyclic moiety such as 59, which could be 
transformed into ABCD rings of the synthetic target; and (3) 
combination of the above two pieces and further 
functionalization to finish 7-con-O-methylnogarol. The 
retrosynthetic analysis is shown in Scheme XIII. 
To synthesize the highly functionalized acyclic ketone 
58 in a specific manner presents a great challenge. There 
are two general strategies for synthesizing acyclic 
skeletons. First, we can modify an already existing linear 
chain or combine two smaller acyclic pieces. Second, we can 
start from a cyclic precursor and cleave it to give the 
linear molecule, a process which is simply a retrosynthesis 
of cyclic compounds from linear precursors. We envisioned 
that the synthesis of ketone 58 could be accomplished 
through the second strategy by using a cyclic carbohydrate 
as a Chiron. The reasons are evident. With carbohydrates 
as starting materials, one has the option of using a cyclic 
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carbon atom framework consisting of 5-7 carbon atoms and 
various asymmetric centers. This provides the flexibility 
to modify the chiron chemically and stereochemically and 
finally leads to the synthesis of ketone 58. 
In the construction of the tetracyclic moiety, we 
foresaw that the presence of a bromine atom at C-2 of the 
naphthacene derivative 59 would be crucial. This allows us 
to transmetallate 59 regiospecifically, and then react with 
ketone 58 to give 57. We also expected the tetracyclic 
compound 59 would be readily available from anhydride 60 and 
bromoquinone 61 followed by a reductive methylation 
procedure developed in our laboratoryWith key 
intermediates 58 and §9 in hand, it was hoped that a Cram 
chelation-controlled addition of an aryl lithium (from 
transmetallation of 59) to ketone 58 would generate both the 
requisite C-5* chirality and incipient C-glycosidic bond. 
The resulting adduct 57 could be transformed into the final 
target 10 with functional group manipulation. 
Ketosugar Preparation 
With the exception of Kawasaki's work, the chemical 
synthesis of nogalamycin and its analogs is a largely 
unexplored area. Our objective was to devise a practical 
and flexible route to these systems. In order to test our 
projected synthetic scheme in a workable manner, it was very 
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important that the key intermediate 58 be obtained in 
manageable quantities. 
In the course of our investigation, we chose cheap, 
commercially available D-arabinose (62) as the starting 
material. Treatment of 62 in refluxing acidic methanol®^ 
yielded methyl pyranoside 63, which was selectively 
% 
5 2  protected as isopropylidene 64. Tosylation of 64 in 
pyridine gave 65. The isopropyli'dene group of compound 65 
was selectively removed in refluxing acidic methanol to give 
alcohol 66. 
rngr "X" rnsr 
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At that stage, although we were confident about the 
configuration of alcohol 66, we still wanted to reaffirm the 
structure of 66 without any ambiguity. To achieve this, we 
prepared compound 67 by treating 66 with acetic anhydride in 
pyridine. Compound 67 was crystalline and could be used for 
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0OCH3 y—o. 0OCH3 
AcO 
OH 
M 
OAc 
X-ray analysis. The X-ray structure determination showed 
that the configuration of compound 67 was what we expected. 
More importantly, the conformation of pyranoside 67 was also 
established from the data we obtained. As shown in Figure 
2, the methoxyl group and acetate group at C-1 and C-4, 
Figure 2. Conformation of pyranoside 67 
respectively, are all in axial positions, while the other 
functional groups at C-2 and C-3 are located equatorially. 
Continuing our synthesis, we displaced a tosyl group 
intramolecularly in compound 66 to afford epoxide 68 in 72% 
'0» 
OCH3 
OTs 
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yield. Opening of the epoxide ring in 68 with dimethylamine 
in ethanol yielded amino alcohol 69 exclusively. 
O OH 
sa sa 
To account for the regiospecific ring opening of epoxide 
68 by the amine, we have to analyze the probable 
conformations of the epoxide 68 and the transition states of 
the intermediates. As shown in Scheme XIV, the epoxide 68 
can exist as two half-chair conformations. In conformation 
I, the hydroxyl and methoxyl groups are in pseudoaxial 
positions, while in conformation II, both groups are located 
pseudoequatorially. The former conformation should be 
relatively more stable than conformation because of the 
anomeric effect and extra stabilization by intramolecular 
hydrogen bonding, which can overcome the unfavorable diaxial 
non-bonding interaction. Hence, in order to explain the 
exclusive 69 formation, we need to consider conformation I 
only. There are two possible pathways of the ring opening 
reaction in conformation I. In path a, the reaction at C-3 
gives chair intermediate with epoxide ring opening and 
thence 69. In path b, the electronically controlled 
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stereochemistry of the transition state in SN2 reaction 
requires that the reaction at C-2 must give the twist-boat 
intermediate which then produces compound 70 after a 
conformational change. The formation of the transition 
state to produce twist-boat intermediate is a higher energy 
process than that in path a. Product 69 is thus formed in 
preference to 70 under kinetically controlled conditions. 
Indeed, it is well known that the epoxide opening gives the 
trans-diaxial products. 
After we obtained the desired amino sugar 69, the 
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alcohol group in 69 was protected as benzyl ether on 
treatment of 69 with sodium hydride and benzyl bromide in 
DMF. With the protected compound 71 in hand, we were ready 
y—OOMe y—o 
oV 
• e
NaH ^ /NMe^ /NMe^OH 
BnBr.DMF 
OBn OBn 
Z1 Z2 
to cleave the acetal to give hemiacetal 72. Several 
reaction conditions were attempted, including acid 
hydrolysis at different concentrations and temperatures, 
trimethylsilyl iodide in methylene chloride, and boron 
trifluoride etherate in THF. None of the conditions gave a 
39 
satisfactory result. We either recovered starting material 
or observed non-selective debenzylated products. 
As a result of the difficulties with compound 71, we 
shifted our attention to different protecting groups but 
retained our initial strategy. Instead of using 
methyl-g-D-arabinopyranoside (63) as starting material, 
benzyl-B-D-arabinopyranoside (73) was our next option. 
Under the same reaction sequence, with only slight 
modifications in experimental conditions, the analogous 
sugar intermediates 73-77 were obtained in good yields and 
summarized in Scheme XV. 
Epoxide 77 underwent nucleophilic ring-opening by 
methylamine in ethanol at 110®C to give amino alcohol 78 
exclusively. The amino group of compound 78 was protected 
as carbamate by treating 78 with ethyl chloroformate and 
NCO2E1 CICOgEI. KaCOs 
OH OH o 
zz za za 
anhydrous potassium carbonate in boiling acetone. 
Scheme XV 
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The two hydroxyl groups in carbamate 79 were protected 
as methoxymethyl ethers by reacting 79 with chloromethyl 
methyl ether and diisopropylethylamine in THF.^® At that 
stage, all the sensitive functionalities have been 
protected. Debenzylation of 80 occurred smoothly with 
catalytic hydrogénation.^^ The resulting cyclic hemiacetal 
81 existed as a mixture of anomers. 
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Mixture 81 was oxidized to lactone 82 by Collins 
reagent.58 Addition of methyl lithium to lactone 82 at 
-78*C yielded cyclic hemiketal 83, which was also a mixture 
similar to hemiacetal 81. At that point, we have 
ai 
Cf03.2Py 
CHjClj 
MOMO 
OMOM 
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successfully prepared compound 83 in reasonable quantity. 
The stereogenic centers at C-2, C-3 and C-4 of 83 will 
become the groups at C-2', C-3', and C-4' respectively of 
the benzoxocin ring system in nogalamycin analogs. 
According to our strategy, the next move is to cleave 
the cyclic precursor into an acyclic ketosugar. We 
envisioned that there is a tremendous difference between the 
reaction rates of primary alcohols and tertiary alcohols, 
when reacted with tert-butyldimethylsilyl chloride to form 
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the corresponding silyl ethers.To achieve our goal 
(converting cyclic sugar 83 into acyclic ketosugar 85), we 
treated 83 with tert-butyldimethylsilyl chloride and 
imadazole in DMF. We got the desired linear ketosugar 85 
via the acyclic ketoalcohol 84. 
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There were a few things worth comment. In the proton 
NMR of 85, we saw two distinct singlets (2.17, 2.22 ppm) 
corresponding to the methyl protons adjacent to the carbonyl 
group. In the corresponding C-13 NMR, we observed two 
carbonyl signals (205.18, 205.28 ppm) corresponding to the 
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carbon atom at C-1. We were curious about these 
observations and wanted to figure out whether it was due to 
epimerization at C-2 of 85 to form two diastereomers, or to 
the restricted rotation on the carbamate group, which leads 
to the formation of two rotamers. 
To prove which hypothesis is correct, we treated 
ketosugar 85 with methyl lithium at -78*C to form alcohol 
86. The resulting 86 was reduced with lithium aluminum 
hydride to give amino alcohol 87. 
-/oB, Y 
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Spectroscopic data on compound 87 suggested that it was 
a single isomer, which supported our second hypothesis, 
i.e., the presence of two methyl signals on compound 85 is 
due to the restricted rotation of the carbamate group. As a 
result, we can declare that we have synthesized the highly 
functionalized ketosugar 85, which is one of our key 
intermediates toward the total synthesis of nogalamycin 
analogs. 
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Synthesis of the Tetracyclic Moiety 
There are numerous different approaches toward the 
construction of ABCD ring portions of anthracyclines. At 
the early stage of our investigation, our approach featured 
a tandem Claisen-Diels-Alder reaction, which was developed 
by our colleagues.^® 
In the preliminary studies, the readily available 
dihydroxyketone 88 was regioselectively alkylated with allyl 
bromide in the presence of potassium carbonate in refluxing 
acetone.The ortho-hydroxyketone 89 was then acylated by 
reacting gg with sodium hydride followed by the acid 
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chloride. The resulting acylated compound was not isolated 
but treated with potassium tert-butoxide directly and 
stirred for an additional hour.®^ The one pot process 
afforded ketone 90 in 62% yield. The next step involved the 
tandem Claisen-Diels-Alder reaction sequence, but the result 
was disappointing. When we prepared 0.01 M solution of 90 
and heated it to 180*C, no reaction occurred. At higher 
temperatures, it led to decomposition of the starting 
material. 
To identify the best reaction conditions for the Claisen 
rearrangement, we heated compound 89 in toluene at various 
temperatures between 150®C and 230®C, but only decomposition 
occurred at prolonged heating above 200®C. However, when 
89 was heated in a solution of acetic anhydride and acetic 
acid at 200°C, Claisen rearrangement proceeded smoothly with 
the formation of diacetate 92. 
ACQ 
ACi»0. HOAc. 200°C , 
OH O 
sa. 
The hydroxyl group of 89 was protected as a methyl ether 
on treatment with excess methyl iodide and potassium 
carbonate,methoxyketone 93 was rearranged to 94 when 
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heated at 200*C. Compound 94 could be a useful intermediate 
for further elaboration to the tetracyclic moiety. 
During the investigation of tandem Claisen-Diels-Alder 
reaction in the naphthalene system, we also directed our 
attention toward the protection of the quinone moiety. In 
addition to their presence as subunits in a variety of 
natural products, quinones are useful building blocks for 
natural product synthesis. Because of the high reactivity 
of quinones, protection of the quinone moiety is often 
required. The protection of a quinone usually involves 
reduction to a hydroquinone followed by protection of the 
hydroquinone. For most compounds the hydroquinone is not 
actually isolated but is treated in situ with an acylating 
agent,64 a methylating agent,or a silylating agent.®® 
The acylated or trimethylsilylated hydroquinones are too 
unstable for multistep sequences. Consequently, the 
reductive methylation technique has become the method of 
choice. The value of this technique is evidenced by several 
recent publications. However, with quinones bearing 
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hydroxyl or alkoxyl groups, the standard reductive 
methylation conditions (NagSgO^, MOgSO^, KgCOg) generally 
proceed poorly. A modification of the standard procedure 
which constitutes a general one for the reductive 
methylation of guinones is thus described. 
The modification involved the use of a phase transfer 
catalyst to improve the solubility of the anion of the 
reduced guinone. As shown in Table 4, even guinones bearing 
hydroxyl or methoxyl groups afforded good yields of the 
reductively methylated products. Notably, a bromine 
substituent was not reduced, as evidenced by entries 4, 5, 
and 9. The only limitation that we have observed is that 
aromatic amines were not compatible with the reaction 
conditions. The reductive methylation of 1,8-dimethoxy-
anthraquinone and 1,4-dihydroxyanthraquinone is significant 
in that the other reductive methylation conditions failed to 
produce any of the respective tetramethoxyanthracene. As 
the example illustrated below indicates, ketones are also 
compatible with the reaction conditions. Protection of the 
reactive hydroxyanthraguinone moiety permits further 
elaboration of the A ring. 
CH3O 
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Table 4. Reductive methylatlon of quinones 
Entry Quinone % Yield Product^ 
1 l-methoxy-6-methylbenzoqulnone 82 
2 1,4-naphthoquinone 94 
3 2-hydroxy-l/4-naphthoquinone 67 
4 2-bromo-3-methyl-l,4-naphthoquinone 88 
5 2-bromo-l,4-naphthoquinone 85 
6 anthraquinone 92 
7 l,4-dihydroxy-9,10-anthraquinone 66 
8 l-hydroxy-4-amino-9,10-anthraquinone 
9 l-methoxy-3-bromo-9flO-anthraquinone 69 
10 l,8-dimethoxy-9,10-anthraquinone 77 
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Coupled with the mild conditions for oxidation of 
hydroquinone dimethyl ethers to quinones developed by 
Rapoport,^^ this procedure will generate new pathways for 
the synthesis of quinonoid compounds. 
As a result of the successful phase transfer reductive 
methylation technique on different kinds of quinones, our 
attention was turned to the preparation of tetracyclic 
compound 59. Of several possible alternatives, Tamura's 
work using strong base-induced cycloaddition of acid 
anhydrides with different naphthoquinones seemed to be very 
attractive. 68 For example, the key tetracyclic quinone 106, 
o 
NaH.THF 
CH3O 
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which can be converted into 11-deoxydaunomycinone (107) and 
11-deoxycarminomycinone (108), was synthesized in only one 
step from naphthoquinone 104 and anhydride 105. 
o HO 
OH OH 
107 RaCHa 
108 R=.H 
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In our synthesis, we started with commercially available 
homophthalic anhydride (60), and naphthoquinone 61, whose 
preparation can be accomplished in three steps from modified 
literature procedures.®^ Bromination of 1,5-dihydroxy-
naphalene in acetic acid at 80°C gave 2,6-dibromo-l,5-
dihydroxynaphthalene in 75% yield. The resulting bromo 
compound was monomethylated to yield compound 109b. 
Oxidation of 109b with chromium trioxide led to quinone 61 
in 55% yield. 
OR OH 
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After the preparation of quinone 61, we attempted to 
conduct the Tamura reaction by adding homophthalic anhydride 
(60) into an LDA solution at -78*C, followed by the addition 
of quinone 61. The reaction proceeded smoothly and the 
resulting adduct 110 was obtained in 75% yield. 
1 LDA. THF 
2H+ 
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Mechanistically, the path involving a Diels-Alder type 
reaction of anhydride to dienophile (path a) is more 
probable than another path involving a Michael addition of 
anhydride to the electron deficient olefin (path b) as 
exemplified in the reaction of the alkaline salt of 60 with 
61 leading to 110 (Scheme XVI), although it is not 
rigorously defined. The attractive feature of the reaction 
is that cycloadduct was obtained in a highly regioselective 
manner, no other regioisomer was isolated. Another 
interesting feature of the reaction is that the intermediate 
underwent spontaneous elimination of COg and HBr in situ to 
form 110. 
After quinone 110 was obtained, we proceeded to the 
phase transfer reductive methylation procedure. Treatment 
of quinone 110 with NagSgO^, NaOH, and MegSO^ in the 
presence of the phase transfer reagent resulted in the 
formation of tetramethoxynapthacene 59 in 55% yield. 
CH3O OCH3 
(n-Bu)4N'*"Br' 
Na2S204, NaOH 
Me2S04 
OCH3 OCH3 
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Studies of the Coupling Reaction 
With ketosugar 85 and tetramethoxynapthacene 59 in hand, 
we proceeded to the coupling reaction. A model study showed 
that an aryl lithium was formed by transmetallation of bromo 
compound 111. Ketosugar 85 was added and the solution was 
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then warmed to 0"C for 20 min. The coupling reaction 
between the aryl lithium and 85 occurred, and the 
corresponding tertiary alcohol 112 was formed. 
Ma 
OMe I 
EtOgCN n/to ,pH OMe 
1 n-BuU 
2 fiS OMOM  ^MOMO 
Although we cannot absolutely prove the configuration of 
the tertiary carbon in 112 at present, based on the Cram 
chelation model,the lithium cation should interact with 
the two oxygen atoms of the MOM group adjacent to the 
carbonyl group of 85 more effectively than the oxygen atom 
of methyl ether in the aromatic ring. Therefore, the usual 
chelation model (Figure 3) should afford the desired 
product. 
112 
Figure 3. Chelation model 
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Removal of the silyl protecting group in 112 was done by 
treating 112 with tetrabutylammonium fluoride in THF. The 
resulting diol 113 was oxidized by Collins reagent to give 
the corresponding lactone 114. 
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The lactone 114 can be oxidized by eerie ammonium 
nitrate in aqueous CHgCN to form an unstable quinone 115 
which is a useful dienophile in Diels-Alder reaction. 
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In the real system, coupling reaction occurred in the 
similar manner, compound 59 was transmetallated with n-butyl 
lithium, followed by addition of ketosugar 85 to the 
resulting aryl lithium to form tertiary alcohol 116. With 
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116 in hand/ we expected desilylation of compound 116 
followed by the oxidation of the resulting product, should 
give lactone 118. 
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CONCLUSION 
Based on our initial strategy to the synthesis of 
nogalamycin analogs, we have achieved some of our goals. 
These include; 
(1) An effective method for synthesizing highly 
functionalized ketosugar from cheap, commercially available 
D-arabinose. This ketosugar contained three contiguous 
stereogenic centers which could be converted into C-2', 3' 
and 4' of the target molecule. 
(2) An approach to the tetracyclic moiety using the 
Tamura reaction, followed by a one pot reductive methylation 
has been developed. This tetracyclic moiety could be 
transformed into ABCD ring of our synthetic target. 
(3) A Cram chelation-controlled coupling reaction 
between the ketosugar and the tetracyclic moiety has been 
achieved. 
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EXPERIMENTAL 
General 
Unless otherwise noted, materials were obtained from 
commercial suppliers and were used without purification. 
TetVahydrofuran (THF) and diethyl ether were distilled from 
sodium benzophenone ketyl prior to usage. Acetone and 
dichloromethane were distilled from phosphorous pentoxide. 
Benzene was distilled from lithium aluminum hydride. 
Pyridine was distilled from calcium hydride. All reactions 
were conducted under a nitrogen atmosphere, and all extracts 
were dried over anhydrous magnesium sulfate. Apparatus for 
experiments requiring anhydrous conditions was flame-dried 
under a steam of nitrogen or was dried in an oven at 150°C 
for 12 hours. Flash chromatography was performed on Grace 
silica gel, grade 62, mesh 60-200. Melting points were 
determined on a Fischer-Johns melting point apparatus and 
are uncorrected. Infrared spectra were obtained on a 
Perkin-Elmer 1320 or Beckman IR-4250 infrared spectro­
photometer. Nuclear magnetic resonance spectra were 
determined on a Varian EM-360 spectrometer. High field (300 
MHz) proton spectra were obtained using a Nicolet Magnetics 
Corporation NMC-1280 spectrometer. All chemical shifts are 
reported in ppm relative to tetramethylsilane as an internal 
standard. Splitting patterns are designated as s (singlet), 
d (doublet), t (triplet), q (quartet) and m (multiplet); 
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addition of b indicates a broadened pattern. C-13 NMR 
spectra were determined on a JOEL FQ-900 or Nicolet NMC-1280 
spectrometer and are reported in ppm relative to the central 
peak of CDClg (77.06 ppm) or Dg-acetone (27,0 ppm). High 
resolution mass spectra were recorded on an AEI-MS 902 high 
resolution mass spectrometer. Low resolution mass spectra 
were recorded on a Finnegan 4023 mass spectrometer. 
Elemental analyses were determined by Galbraith 
Laboratories, Inc. 
Acetonide 64 
To a stirred solution of sugar 63 (5.0 g, 3.05 mmol) in 
acetone (30 mL) at room temperature was added 
2,2-dimethoxypropane (10 mL) and PTSA (0.19 g, 1.0 mmol). 
After stirring for 12 h, triethylamine (1 mL) was added, and 
stirring was continued for 5 min. The solution was 
concentrated in vacuo. To the residue was added 10 mL of 
water, and the resulting suspension was repeatedly extracted 
with dichloromethane. The combined extracts were washed 
with brine, dried over anhydrous magnesium sulfate, filtered 
and concentrated jji vacuo to give a yellow oily liquid, 
which was purified via flash column chromatography using 1:1 
hexanes:ethyl acetate as eluent to obtain compound 64 (4.7 
g, 75%) as an oil. NMR (CDCI3) 5 4.68 (d, 1 H, J = 3.6 Hz), 
4.10-4.21 (m, 2 H), 3.80-3.90 (m, 2 H), 3.74 (dd, 1 H, J = 
3.6 and 6.3 Hz), 3.41 (s, 3 H), 2.33 (bs, 1 H), 1.50 (s, 3 
59 
H), 1.33 (s, 3 H). IR (neat) 3450, 2920, 1465, 1450, 1260, 
1030, 906 cm High resolution mass spectrum for CgH^gOg 
(M*-H) requires 203.09195; measured 203.09161. C-13 NMR 
(CDCI3) 6 108.83, 98.90, 75.93, 72.89, 70.01, 59.12, 55.46, 
27.85, 25.88. 
Tosylate 65 
To a vigorously stirred solution of compound 64 (10.0 g, 
49.0 mmol) in pyridine (100 mL) at room temperature was 
added p-toluenesulfonyl chloride (14.0 g, 73.5 mmol) in one 
portion. After stirring for 48 h, the resulting reaction 
mixture was concentrated in vacuo. To the residue was added 
100 mL of water, and the resulting suspension was repeatedly 
extracted with dichloromethane. The combined extracts were 
washed with water and brine, dried over anhydrous magnesium 
sulfate, filtered and concentrated in_ vacuo to give a white 
solid. Recrystallization of this substance from 1:1 
hexanes:ethanol afforded 65 (16.1 g, 92%) as colorless 
crystals (mp 136-137'C). NMR (CDCI3) 6 7.83 (d, 2 H, J = 
8.4 Hz), 7.32 (d, 2 H, J = 8.4 Hz), 4.85 (d, 1 H, J = 3.0 
Hz), 4.15-4.31 (m, 3 H), 3.85-3.97 (m, 2 H), 3.36 (s, 3 H), 
2.42 (s, 3 H), 1.23 (s, 3 H), 1.10 (s, 3 H). IR (film) 
2930, 1585, 1370, 1195, 1172, 1020, 945 cm"^. High 
resolution mass spectrum for ^15^22^7'^ requires 358.10863; 
measured 358.10885. C-13 NMR (CDCI3) 5 144.68, 132.93, 
129.41, 127.97, 108.83, 97.36, 78.85, 73.64, 72.31, 57.87, 
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55,53, 27.17, 25.85, 21.30. Elemental analysis calculated 
for ^16^22^7'^* 53*62; H, 6.19. Found: C, 53.37; H, 
6.05. 
Alcohol 66 
A mixture of compouhd 65 (6.0 g, 16.8 mmol), methanol 
(200 mL), water (5 mL) and 6 N hydrochloric acid (8 mL) was 
heated at reflux with stirring for 12 h. The mixture was 
cooled to room temperature, pyridine (10 mL) was added and 
the reaction mixture was concentrated in vacuo. The residue 
was dissolved in dichloromethane (250 mL), washed with 
brine, dried over anhydrous magnesium sulfate and 
concentrated in vacuo to give a yellow oil, which was 
purified via flash column chromatography using 1:1 
hexanes: ethyl acetate as eluent to afford compound 66 (4.7 
g, 88%) as a viscous oil. NMR (CDClg) 5 7.84 (d, 2 H, J = 8 
Hz), 7.36 (d, 2 H, J = 8 Hz), 4.63 (bs, 1 H), 4.60 (m, 1 H), 
3.96-4.09 (m, 2 H), 3.66-3.81 (m, 2 H), 3.29 (s, 3 H), 2.46 
(s, 3 H). IR (neat) 3450, 3050, 2960, 1590, 1350, 1185, 
1170, 1130, 1005, 940 cm~^. Mass spectrum m/e 318, 269, 
155, 131, 103, 61. High resolution mass spectrum for 
C13H19O7S (MH*) requires 319.08516; measured 319.08549. 
C-13 NMR (CDCI3) 6 144.78, 133.16, 129.50, 127.58, 97.34, 
78.07, 69.34, 66.50, 61.77, 55.08, 21.26. 
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Acetate 67 
To a stirred solution of compound 66 (9.5 g, 29.9 mmol) 
in pyridine (40 mL) at room temperature was added acetic 
anhydride (20 mL). After stirring for 12 h the reaction 
mixture was cooled to 0*C, methanol (20 mL) was added to 
destroy the unreacted acetic anhydride. Stirring was 
continued for 10 min. The solution was concentrated in 
vacuo. To the residue was added 100 mL of water, and the 
resulting suspension was repeatedly extracted with 
dichloromethane. The combined extracts were washed with 
water and brine, dried over anhydrous sodium sulfate, 
filtered and concentrated in. vacuo to give a white solid. 
Recrystallization of this substance from 1:1 hexanes;ethyl 
acetate afforded pure 67 (11.3 g, 94%) as colorless crystals 
(mp 112-114°C). NMR (CDCI3) 6 7.76 (d, 2 H, J = 8 Hz), 7.31 
(d, 2 H, J = 8 Hz), 5.23-5.26 (m, 2 H), 4.74-4.82 (m, 2 H), 
3.84 (d, 1 H, J = 13 Hz), 3.58 (dd, 1 H, J = 1.5 and 13 Hz), 
3.29 (s, 3 H), 2.41 (s, 3 H), 2.06 (s, 3 H), 1.74 (s, 3 H). 
IR (film) 3020, 2930, 1740, 1590, 1360. Mass spectrum m/e 
402, 247, 187, 155, 127, 85. High resolution mass spectrum 
for C^^HggOgS (MH^) requires 403.10629; measured 403.10629. 
C-13 NMR (CDCI3) 6 170.02, 169.49, 144.99, 133.78, 129.67, 
127.82, 98.04, 74.44, 69.39, 66.51, 60.13, 55.74, 21.61, 
20.83, 20.38. 
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Epoxide 68 
A freshly prepared 1.0 N solution of sodium methoxide in 
methanol (75 mL) was poured into a flask containing compound 
66 (6.0 g, 18.9 mmol) and methanol (25 mL) at room 
temperature. After stirring for 12 h/ the basic solution 
was neutralized with acetic acid. The resulting solution 
was concentrated jji vacuo. The residue was washed 
thoroughly with diethyl ether and filtered. The filtrate 
was concentrated in vacuo to give an oil, which was purified 
via flash column chromatography using 2:1 hexanes:ethyl 
acetate as eluent to obtain compound 68 (2.4 g, 87%) as a 
colorless oil. NMR (CDClg) 6 4.80 (bs, 1 H), 3.87 (m, 1 H), 
3.73 (dd, 1 H, J = 3 and 12 Hz), 3.50 (t, 1 H, J = 4 Hz), 
3.43 (s, 3 H), 3.39 (d, 1 H, J = 12 Hz), 3.71 (d, 1 H, J = 4 
Hz). IR (neat) 3450, 2920, 1400, 1240, 1082, 1058, 1025, 
970 cm ^. Mass spectrum m/e 146, 115, 85, 69, 58. High 
resolution mass spectrum for CgH^gO^ requires 146.05791; 
measured 146.05792. C-13 NMR (CDCI3) 6 95.43, 61.75, 61.70, 
55.79, 51.79. 
Amine 69 
To a stirred solution of epoxide 68 (1.0 g, 6.8 mmol) in 
ethanol (20 mL) at 0°C in a culture tube was added dimethyl 
amine (2 mL). The solution was deoxygenated and heated at 
110®C for 20 h. The reaction mixture was cooled to room 
temperature and concentrated in_ vacuo. The crude product 
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was dissolved in hot chloroform (10 mL), followed by the 
addition of hexanes (30 mL). The resulting mixture was 
refrigerated and the product (1.1 g, 84%) was collected 
through suction filtration as white powder (mp 79-81"C). 
NMR (CDCI3) S 4.13 (d, 1 H, J = 7.5 Hz), 4.04 (dd, 1 H, J = 
5 and 11 Hz), 3.43-3.64 (m, 4 H), 3.22 (t, 1 H, J = 11 Hz), 
2.5? (s, 6 H), 2.40 (t, 1 H, J = 10 Hz). IR (film) 3050, 
2940, 1075, 1030 cm~^. Mass spectrum m/e 191, 159, 129, 
117, 87, 72, 58. High resolution mass spectrum for CgH^^NO^ 
requires 119.11576; measured 119.11553. C-13 NMR (CDCI3) 6 
105.66, 70.47, 69.75, 67.09, 65.05, 56.87, 41.64. 
Ether 71 
To a suspension of hexane-washed sodium hydride (0.41 g, 
17.1 mmol) in DMF (20 mL) at 0°C under nitrogen atmosphere 
was added compound 69 (1.0 g, 5.2 mmol). The reaction 
mixture was stirred at 0°C for 10 min and benzyl bromide 
(1.97 g, 12.5 mmol) was added. The reaction mixture was 
warmed to room temperature. After stirring for 8 h, the 
reaction mixture was poured into ice water and was 
repeatedly extracted with dichloromethane. The combined 
extracts were washed with water and brine, dried over 
anhydrous sodium sulfate, filtered, concentrated _in vacuo to 
give a yellow oil. The crude product was purified via flash 
column chromatography using 4:1 hexanes:ethyl acetate as 
eluent to afford compound 71 (1.8 g, 92%) as a viscous 
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liquid. NMR (CDCI3) 6 7.24-7.40 (m, 10 H), 4.85 (d, 1 H, J 
= 11 Hz), 4.71 (d, 1 H, J = 11 Hz), 4.68 (d, 1 H, J = 11 
Hz), 4.59 (d, 1 H, J = 11 Hz), 4.24 (d, 1 H, J = 7 Hz), 3.93 
(dd, 1 H, J = 5 and 11 Hz), 3.45-3.56 (m, 1 H), 3.50 (s, 3 
H), 3.29 (dd, 1 H, J = 7 and 10 Hz), 3.20 (dd, 1 H, J = 10 
and 11 Hz), 2.47 (s, 6 H). IR (neat) 3020, 1590, 1350, 
1170, 1010, 930 cm~^. Mass spectrum m/e 371, 280, 188, 148, 
91, 58. High resolution mass spectrum for C22H29NO4 
requires 371.20967; measured 371.20974. C-13 NMR (CDCl^) 6 
138.82, 138.50, 128.38, 128.23, 128.08, 127.92, 127.72, 
127.46, 106.21, 77.64, 73.66, 73.34, 72.53, 69.52, 64.96, 
56.77, 42.05. 
Acetonide 74 
To a stirred solution of compound 73 (20.0 g, 83.3 mmol) 
in acetone (150 mL) at room temperature was added 
2,2-dimethoxypropane (30 mL) and PTSA (0.5 g, 2.6 mmol). 
After stirring for 12 h, triethylamine (1 mL) was added and 
stirring was continued for 5 min. The solution was 
concentated In vacuo. To the residue was added 30 mL of 
water, and the resulting suspension was repeatedly extracted 
with dichloromethane. The combined extracts were washed 
with brine, dried over anhydrous magnesium sulfate, filtered 
and concentrated In vacuo to give a yellow oily liquid, 
which was purified via flash column chromatography using 2:1 
hexanes:ethyl acetate as eluent to obtain compound 74 (20.7 
65 
g, 89%) as a viscous oil. NMR (CDCI3) S 7.25-7.50 (m# 5 H), 
4.92 (d, 1 H, J = 3.6 Hz), 4.78 (d, 1 H, J = 12 Hz), 4.54 
(d, 1 H, J = 12 Hz), 4.16-4.22 (m, 2 H), 3.88-4.03 (m, 2 H), 
3.76-3.81 (m, 1 H), 1.52 (s, 3 H), 1.35 (s, 3 H), IR (neat) 
3450, 3020, 2910, 1443, 1370, 1240, 1210, 848 cm~^. Mass 
spectrum m/e 280, 265, 189, 156, 131, 91, 59. High 
resolution mass spectrum for C^gHggOg requires 280.13108; 
measured 280.13172. C-13 NMR (CDCI3) 6 136.88, 128.21, 
128.12, 127.68, 108.80, 96.90, 75.69, 72.76, 69.83, 69.39, 
59.40, 27.71, 25.76. 
Tosylate 75 
To a vigorously stirred solution of compound 74 (19.0 g, 
67.9 mmol) in pyridine (150 mL) at room temperature was 
added p-toluenesulfonyl chloride (19.4 g, 101.8 mmol) in one 
portion. After stirring for 48 h, the resulting suspension 
was concentrated in vacuo. To the residue was added 150 mL 
of water, and the suspension was repeatedly extracted with 
dichloromethane. The combined extracts were washed with 
water and brine, dried over anhydrous magnesium sulfate, 
filtered and concentrated in. vacuo to give a syrup, which 
was purified via flash column chromatography using 3:1 
hexanes:ethyl acetate as eluent to yield compound 75 (27.1 
g, 92%) as a viscous liquid. NMR (CDClg) 5 7.78 (d, 2 H, J 
= 8 Hz), 7.33 (m, 5 H), 7.28 (d, 2 H, J = 8 Hz), 5.04 (d, 1 
H, J = 1.5 Hz), 4.68 (d, 1 H, J = 12 Hz), 4.48 (d, 1 H, J = 
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12 Hz), 4.30-4.32 (m, 2 H), 4.15-4.19 (m, 1 H), 3.95 (m, 2 
H), 2.41 (s, 3 H), 1.25 (s, 3 H), 1.14 (s, 3 H). IR (neat) 
3020, 2975, 2920, 1590, 1490, 1447, 1360, 1305, 1240, 1130, 
1065, 1010, 940, 830 cm ^. Mass spectrum m/e 434, 419, 359, 
315, 279, 239, 204, 174, 143, 91, 65. High resolution mass 
spectrum for ^22^26^7® ï"®Quires 434.13993; measured 
434.13909. C-13 NMR (CDCI3) 6 144.73, 136.66, 133.19, 
129.60, 128.40, 128.23, 127.90, 127.72, 109.19, 95.84, 
78.84, 72.66, 70.04, 58.59, 27.47, 26.16, 21.61. 
Alcohol 76 
To a solution of compound 75 (15.0 g, 34.6 mmol) in 
methanol (200 mL) was added 6 N hydrochloric acid (5 mL). 
The solution was refluxed for 8 h, cooled to room 
temperature, and pyridine (10 mL) was added. Stirring was 
continued for 10 min. The solution was concentrated in 
vacuo. To the residue was added 50 mL of water, and the 
resulting mixture was repeatedly extracted with 
dichloromethane. The combined extracts were washed with 
brine, dried over anhydrous magnesium sulfate, filtered and 
concentrated in vacuo to give a syrup. Chromatography on 
silica gel using 1:2 diethyl ether:ethyl acetate as eluent 
afforded compound 76 (12.9 g, 95%) as a sticky substance. 
NMR (CDCI3) S 7.72 (d, 2 H, J = 8 Hz), 7.27-7.40 (m, 5 H), 
7.25 (d, 2 H, J = 8 Hz), 4.80 (d, 1 H, J = 3.6 Hz), 4.66 (d, 
1 H, J = 12 Hz), 4.63 (dd, 1 H, J = 3.6 and 10 Hz), 4.37 (d, 
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1 H, J = 12 Hz), 4.12 (dd, 1 H, J = 3.6 and 10 Hz), 4.01 (t, 
1 H, J = 1.5 Hz), 3.84 (d, 1 H, J = 13 Hz), 3.71 (dd, 1 H, J 
= 1.5 and 13 Hz), 3.102 (bs, 1 H), 2.90 (bs, 1 H), 2.41 (s, 
3 H). IR (neat) 3350, 3020, 2920, 1590, 1448, 1350, 1170, 
1133, 1060, 1010, 940, 860 cm"^. Mass spectrum m/e 394, 
377, 317, 269, 245, 173, 155, 91. High resolution mass 
spectrum for C^^Hg^SOy (MH*) requires 395.11646; measured 
395.11657. C-13 NMR (CDCI3) 6 144.87, 136.75, 133.10, 
129.68, 128.23, 127.74, 127.66, 95.82, 78.06, 69.43, 66.88. 
Epoxide 77 
To a well stirred solution of alcohol 76 (5.6 g, 14.2 
mmol) in methanol (50 mL) was added sodium methoxide (2.3 g, 
42.6 mmol) at room temperature. After stirring for 12 h, 
the basic solution was neutralized with acetic acid. The 
solution was concentrated Ijl vacuo. To the residue was 
added 30 mL of water, and the resulting mixture was 
repeatedly extracted with dichloromethane. The combined 
extracts were washed with water and brine, dried over 
anhydrous magnesium sulfate, filtered and concentrated in 
vacuo to give a yellow solid, which was purified via column 
chromatography using 2:1 hexanes;ethyl acetate as eluent to 
obtain compound 77 (2.7 g, 86%) as a white powder (mp 
77-79°C). NMR (CDCI3) 6 7.25-7.42 (m, 5 H), 5.02 (s, 1 H), 
4.78 (d, 1 H, J = 12 Hz), 4.58 (d, 1 H, J = 12 Hz), 
3.80-3.95 (m, 2 H), 3.50 (t, 1 H, J = 4 Hz), 3.42 (d, 1 H, J 
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= 12 Hz), 3.22 (d, 1 H, J = 4 Hz), 3.10 (bd, 1 H, J = 10 
Hz). IR (neat) 3450, 3040, 2960, 1490, 1445, 1397, 1260, 
1145, 1120, 1080, 1052, 1015, 972 cm ^. Mass spectrum m/e 
222, 161, 133, 107, 91, 73, 65. High resolution mass 
spectrum for ^22^2404 requires 222.08921; measured 
222.08966. C-13 NMR (CDCI3) 5 136.92, 128.41, 128.00, 
127.91, 93.53, 69.98, 62.04, 61.64, 51.85, 51.83. 
Amine 78 
To a solution of epoxide 77 (4.5 g, 20.3 mmol) in 
ethanol (50 mL) in a culture tube was saturated with 
methylamine. The solution was heated at 110°C for 18 h. 
After cooling to room temperature, the resulting mixture was 
concentrated in. vacuo. The residue was dissolved in hot 
chloroform (20 mL). To the resulting hot solution was added 
hexanes (100 mL) and refrigerated. The amine 78 (4.6 g, 
90%) was collected through suction filtration as a white 
solid (mp 150-151*C). NMR (CDCI3) 6 7.25-7.42 (m, 5 H), 
4.87 (d, 1 H, J = 11 Hz), 4.56 (d, 1 H, J = 11 Hz), 4.40 (d, 
1 H, J = 6.6 Hz), 4.06 (dd, 1 H, J = 4.5 and 11 Hz), 3.64 
(m, 1 H), 3.50 (dd, 1 H, J = 6.5 and 3.3 Hz), 3.30 (dd, 1 H, 
J = 8.7 and 11 Hz), 2.48 (t, 1 H, J = 8.7 Hz), 2.44 (s, 3 
H). IR (film) 3400, 3020, 2940, 1600, 1480, 1240, 1115, 960 
cm ^. Mass spectrum m/e 253, 191, 145, 91. High resolution 
mass spectrum for C^gH^gO^N requires 253.13141; measured 
253.13124. C-13 NMR (CDCI3) 6 137.11, 128.58, 128.15, 
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70.06, 66.80, 66.24, 64.36, 32.13. Elemental analysis 
calculated for C, 61.64; H, 7.56. Found: C, 
61.52; H, 7.29. 
Carbamate 79 
To a stirred suspension of amine 78 (6.8 g, 26.9 mmol) 
in acetone (50 rr.L) was added anhydrous potassium carbonate 
8.2 g, 50.1 mmol) and ethyl chloroformate (2.8 mL, 29.6 
mmol). The reaction mixture was refluxed for 8 h, cooled to 
room temperature, filtered and concentrated in vacuo. The 
crude product was dissolved in chloroform (20 mL). To the 
resulting solution was added hexanes (150 mL) and 
refrigerated. The carbamate 79 (8.1 g, 93%) was collected 
through suction filtration as a white powder (mp 119-120°C). 
NMR (CDCI3) S 7.26-7.43 (m, 5 H), 4.91 (d, 1 H, J = 11 Hz), 
4.61 (d, 1 H, J = 11 Hz), 4.36 (d, 1 H, J = 7.5 Hz), 
4.00-4.20 (m, 4 H), 3.77 (m, 1 H), 3.52 (m, 1 H), 3.26 (t, 1 
H, J = 10 Hz), 2.88 (s, 3 H), 2.65 (bs, 1 H), 1.26 (t, 3 H, 
J = 7 Hz). IR (film) 3450, 3020, 2960, 1650, 1480, 1420, 
1335, 1280, 1233, 1145, 1050, 970 cm~^. Mass spectrum m/e 
325, 310, 217, 188, 170, 91. High resolution mass spectrum 
for C^gHg^NOg requires 325.15254; measured 325.15301. C-13 
NMR (CDClg) 6 158.86, 136.95, 128.46, 128.04, 127.96, 
103.21, 70.96, 68.96, 67.38, 65.77, 62.95, 61.96, 28.64. 
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Ether 80 
To a well stirred solution of compound 79 (8.1 g, 24.9 
mmol) in THF (30 mL) and diisopropylethylamine (17.3 mL, 
99.6 mmol) at room temperature was added chloromethyl methyl 
ether (5.7 mL, 74.8 mmol). After stirring for 24 h, 50 mL 
of water was added and the resulting suspension was 
repeatedly extracted with dichloromethane. The combined 
extracts were washed with water and brine, dried over 
anhydrous magnesium sulfate, filtered and concentrated ia, 
vacuo to give an orange oil. The crude product was purified 
via flash column chromatography to afford compound 80 (9.8 
g, 95%) as a slight yellow liquid. NMR (CDClg) 6 7.20-7.26 
(m, 5 H), 4.96 (d, 1 H, J = 7 Hz), 4.88 (d, 1 H, J = 12 Hz), 
4.51-4.65 (m, 5 H), 4.45 (d, 1 H, J = 7 Hz), 4.00-4.23 (m, 4 
H), 3.30-3.40 (m, 2 H), 3.31 (s, 3 H), 3.27 (s, 3 H), 2.90 
(s, 3 H), 1.20-1.29 (m, 3 H). IR (neat) 3010, 2940, 1680, 
1449, 1400, 1370, 1320, 1215, 1145, 915 cm~^. Mass spectrum 
m/e 413, 322, 289, 246, 222, 189, 170, 116, 91, 59. High 
resolution mass spectrum for C^QHg^OgN requires 413.20498; 
measured 413.20424. C-13 NMR (CDCI3) S 156.59, 136.88, 
136.78, 127.74, 127.03, 103.09, 96.33, 96.29, 95.56, 73.28, 
70.68, 70.25, 70.21, 64.81, 60.68, 60.49, 59.53, 54.93, 
54.68, 54.57, 27.16, 14.17. 
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Hemiacetal 81 
To a suspension of compound 80 (9.5 g, 23.0 mmol) and 
activated 10% Pd/C (0.6 g) in ethanol (100 mL) was 
hydrogenated at 50 psi for 8 h at room temperature. The 
resulting suspension was filtered through celite. The 
filter cake was washed thoroughly with methanol (3 x 20 mL) 
and the combined filtrate was concentrated in. vacuo. The 
crude product was purified via flash column chromatography 
using 1:1 hexanes:ethyl acetate as eluent to yield compound 
81 (7.1 g, 96%) as a viscous liquid. NMR (CDClg) 6 5.3 (m, 
1 H), 4.45-4.70 (m, 5 H), 3.39-4.22 (m, 4 H), 3.60-3.81 (m, 
3 H), 3.33-3.41 (m, 2 H), 3.32, 3.30, 3.27 and 3.26 (s, 6 
H), 2.89 (bs, 3 H), 1.16-1.32 (m, 3 H). IR (neat) 3450, 
2940, 1690, 1441, 1405, 1372, 1320, 1135, 1097, 1025, 915 
cm"^. Mass spectrum m/e 323, 292, 278, 246, 216, 202, 148, 
116, 72. High resolution mass spectrum for 
required 323.15802; measured 323.15778. C-13 NMR (CDCl^) 5 
157.40, 98.31, 96.91, 96.37, 96.24, 96.11, 92.50, 91.23, 
91.09, 75.66, 73.63, 71.57, 71.15, 71.08, 70.67, 65.42, 
65.32, 61.49, 61.27, 61.11, 60.46, 60.33, 60.18, 55.57, 
55.44, 55.38, 55.22, 27.80, 14.60. 
Lactone 82 
To a well stirred solution of dry pyridine (23.1 mL, 286 
mmol) in dichloromethane (300 mL) at 0®C was added chromium 
trioxide (14.3 g, 143 mmol) in portions under nitrogen 
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atmosphere. Stirring was continued for 10 min at room 
temperature after complete addition. Compound 81 (7.7 g, 
23.8 mmol) in dichloromethane (50 mL) was added to the 
freshly prepared Collins reagent solution and the reaction 
mixture was stirred for 60 min. The dark mixture was passed 
through a column containing silica gel with ethyl acetate as 
solvent and the combined solution was concentrated .ijj vacuo. 
The resulting crude product was purified via flash column 
chromatography using 1:1 hexanes:ethyl acetate as eluent to 
yield compound 82 (7.0 g, 95%) as an oily liquid. NMR 
(CDCI3) 6 5.09 (d, 1 H, J = 11 Hz), 4.90 (m, 1 H), 4.62-4.78 
(m, 4 H), 4.30-4.45 (m, 2 H), 4.09-4.25 (m, 3 H), 3.39 (s, 3 
H), 3.35 (s, 3 H), 3.11 (s, 3 H), 1.29 (t, 3 H, J = 7 Hz). 
IR (neat) 2940, 1758, 1682, 1460, 1395, 1340, 1300, 1252, 
1210, 1171, 1148, 1120, 1095, 1023, 913 cm"^. Mass spectrum 
m/e 321, 276, 202, 160, 114, 70. High resolution mass 
spectrum for C^gHggOgN requires 321.14237; measured 
321.14228. C-13 NMR (CDCI3) 6 170.79, 155.58, 95.69, 95.25, 
75.14, 69.44, 67.78, 66.41, 61.20, 55.23, 37.64, 14.27. 
Hemiketal 83 
To a stirred solution of lactone 82 (7.0 g, 21.8 mmol) 
in THF (40 mL) at -78*C was added methyl lithium (28.3 mL, 
28.3 mmol) slowly. After stirring at -78°C for 5 h, the 
reaction mixture was quenched with 2 N ammonium chloride (20 
mL). The resulting mixture was repeatedly extracted with 
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dichloromethane. The combined extracts were washed with 
brine, dried over anhydrous magnesium sulfate, filtered and 
concentrated in vacuo to give a yellow oil, which was 
purified via flash column chromatography using 1:1 
hexanes:ethyl acetate as eluent to yield compound 83 (6.4 g, 
87%) as a viscous liquid. NMR (CDCl^) 6 4.45-4.75 (m, 5 H), 
4.18-4.27 (m, 3 H), 3.70-3.86 (m, 2 H), 3.40-3.42 (m, 1 H), 
3.36 (bs, 3 H), 3.31 (bs, 3 H), 2.88 (bs, 3 H), 3.48 and 
3.45 (s, 3 H), 1.26 (t, 3 H, J = 7 Hz). IR (neat) 3450, 
2922, 1675, 1460, 1440, 1400, 1370, 1305, 1145, 1090, 1024, 
915 cm""^. High resolution mass spectrum for C^^HgyOgN 
requires 337.17371; measured 337.17382. C-13 NMR (CDCl^) S 
157.57, 99.65, 98.03, 97.67, 97.42, 97.20, 96.60, 96.34, 
96.23, 96.16, 79.07, 78.14, 77.94, 77.79, 72.97, 71.74, 
71.20, 65.09, 62.22, 61.88, 61.81, 61.49, 61.40, 61.15, 
57.92, 56.39, 56.11, 55.68, 55.44, 55.30, 40.53, 27.96, 
26.44, 14.70. 
Ketone 85 
To a stirred solution of hemiketal 83 (6.5 g, 19.3 mmol) 
in DMF (50 mL) was added imidazole (3.9 g, 57.9 mmole) and 
tert-butyldimethylsilyl chloride (3.8 g, 25.2 mmol). After 
stirring at room temperature for 24 h, 30 mL of water was 
added and the resulting mixture was repeatedly extracted 
with dichloromethane. The combined extracts were washed 
with water and brine, dried over anhydrous magnesium 
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sulfate, filtered and concentrated jji vacuo to give a yellow 
oily liquid, which was purified via flash column 
chromatography using 4:1 hexanes:ethyl acetate as eluent to 
yield compound 85 (8.7 g, 100%) as a colorless oil. NMR 
(CDCI3) S 5.15 and 4.98 (dd, 1 H), 4.38-4.82 (m, 4 H), 
4.05-4.18 (m, 2 H), 3.73-3.97 (m, 3 H), 3.37 (a, 3 H), 3.35 
(s, 3 H), 3.35-3.39 (m, 1 H), 2.92 and 2.90 (s, 3 H), 2.22 
and 2.17 (s, 3 H), 1.17-1.30 (m, 3 H), 0.93 (s, 9 H), 0.11, 
0.10, 0.09 and 0.08 (s, 6 H). IR (neat) 2920, 1725, 1700, 
1470, 1440, 1400, 1317, 1250, 1210, 1150, 1025, 920, 835 
cm~^. Mass spectrum 451, 394, 334, 274, 232, 190, 158, 116, 
89. High resolution mass spectrum for CggH^gOgNSi (M*-H) 
requires 450.25233; measured 450.25312. C-13 NMR (CDCI3) 6 
205.28, 205.18, 157.38, 156.97, 99.26, 96.60, 96.42, 96.19, 
81.84, 81.71, 75.36, 75.29, 62.34, 61.71, 61.25, 56.33, 
55.67, 55.21, 55.10, 30.76, 30.54, 26.56, 26.19, 25.67, 
25.63, 18.00, 17.96, 17.68, 14.42, -5.73, -5.59. 
Alcohol 86 
To a solution of compound 85 (1.0 g, 2.2 mmol) in THF 
(15 mL) at -78°C was added methyl lithium (2.9 mL, 4.4 mmol) 
slowly. After stirring at -78°C for 5 h, the reaction 
mixture was quenched with 2 N ammonium chloride (10 mL). 
The resulting mixture was repeatedly extracted with 
dichloromethane. The combined extracts were washed with 
water and brine, dried over anhydrous magnesium sulfate. 
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filtered and concentrated in. vacuo to give an oil, which was 
purified via flash column chromatography using 3:1 
hexanes:ethyl acetate as eluent to afford compound 86 (0.9 
g, 88%) as a colorless oil. NMR (CDClg) 6 4.51-4.80 (m, 5 
H), 4.07-4.19 (m, 2 H), 3.50-3.91 (m, 4 H), 3.44 and 3.42 
(s, 3 H), 3.33 (s, 3 H), 2.92 and 2.91 (s, 3 H), 1.60 (bs, 1 
H), 1.17-1.25 (m, 9 H), 0.88 (s, 9 H), 0.06 (s, 3 H), 0.04 
(s, 3 H). IR (neat) 3460, 2900, 1675, 1465, 1310, 1250, 
1210, 830 cm"^. Mass spectrum m/e 467, 436, 410, 334, 232, 
190, 161, 116, 89, 73. High resolution mass spectrum for 
^21^46^8^®^ (MH^) requires 468.29929; measured 468.29881. 
C-13 NMR (CDCI3) 6 157.52, 157.20, 99.75, 99.53, 96.21, 
95.85, 89.25, 88.96, 76.71, 75.96, 72.34, 72.24, 63.03, 
62.01, 60.98, 55.71, 55.56, 55.33, 55.03, 54.89, 31.15, 
3Q.92, 25.51, 25.24, 25.12, 24.07, 17.88, 17.83, 14.44, 
14.23, -5.79. 
Amine 87 
To a stirred suspension of lithium aluminum hydride (182 
mg, 4.8 mmol) in diethyl ether (10 mL) was added compound 
86 (560 mg, 1.2 mmol) in diethyl ether (2 mL) at 0*C. The 
reaction mixture was heated at reflux for 5 h, cooled to 
-78°C, diluted with ether (20 mL) and quenched with 2 N 
ammonium chloride (4 mL). The reaction mixture was filtered 
through eelite and the filter cake was washed thoroughly 
with ether (4 x 20 mL). The combined filtrate was washed 
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with brine, dried over anhydrous magnesium sulfate, filtered 
and concentrated in, vacuo to give a yellow oil, which was 
purified via flash column chromatography using 3:1 
hexanes:ethyl acetate as eluent to afford compound 87 (407 
mg, 83%) as a viscous liquid. NMR (CDCI3) 5 4.81 (d, 1 H, J 
= 7 Hz), 4.80 (d, 1 H, J = 7 Hz), 4.74 (d, 1 H, J = 7 Hz), 
4.00 (m, 2 H), 4.86 (dd, 1 H, J = 2.5 and 12 Hz), 3.44 (s, 3 
H), 3.38 (s, 3 H), 3.16 (d, 1 H, J = 2 Hz), 2.58 (s, 6 H), 
2.55-2.57 (m, 1 H), 1.23 (s, 3 H), 1.15 (s, 3 H), 0.87 (s, 9 
H), 0.06 (s, 3 H), 0.04 (s, 3 H). IR (neat) 3460, 2920, 
1462, 1250, 1145, 1025, 957 cm~^. Mass spectrum 409, 352, 
276, 190, 100, 73, 58. High resolution mass spectrum for 
^19^42^6^^^^ (M^-H) requires 408.27815; measured 408.27890. 
C-13 NMR (CDCI3) 6 100.29, 96.83, 85.25, 79.59, 73.79, 
62.37, 62.13, 56.43, 56.29, 43.31, 29.76, 29.05, 27.64, 
25.98, 18.34, -5.34. 
Ketone 89 
To a stirred suspension of compound 88 (265 mg, 1.31 
mmol) and anhydrous potassium carbonate (181 mg, 1.31 mmol) 
in acetone (10 mL) at room temperature was added allyl 
bromide (169 mg, 1.40 mmol). The reaction mixture was 
heated at reflux for 7 h, poured into ice water and 
acidified with 2 N hydrochloric acid. The aqueous mixture 
was repeatedly extracted with dichloromethane. The combined 
extracts were washed with water and brine, dried over 
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anhydrous sodium sulfate, filtered and concentrated in, vacuo 
to give a brown residue, which was purified via flash column 
chromatography using 3:1 hexanes:ethyl acetate as eluent to 
yield compound 89 (267 mg, 84%) as a bright yellow powder 
(mp 103-105*C). NMR (CDCI3) 6 13.74 (s, 1 H), 8.44 (d, 1 
H, J = 8 Hz), 8.23 (d, 1 H, J = 8 Hz), 7.66 (t, 1 H, J = 8 
Hz), 7.57 (t, 1 H, J = 8 Hz), 6.88 (s, 1 H), 6.18 (m, 1 H), 
5.52 (bd, 1 H, J = 17 Hz), 5.36 (bd, 1 H, J = 11 Hz), 4.69 
(bd, 2 H, J = 5.4 Hz), 2.66 (s, 3 H). IR (film) 3300, 3020, 
2936, 1670, 1480, 1160 cm~^. Mass spectrum m/e 242, 230, 
201, 183, 173, 155, 127, 102, 77, 51. High resolution mass 
spectrum for C^gH^^Og requires 242.09430; measured 
242.09427. C-13 NMR (CDCI3) 6 203.66, 157.52, 146.27, 
133.37, 130.58, 129.79, 126.64, 126.02, 124.43, 122.04, 
117.60, 112.00, 102.82, 69.60, 27.07. 
Diketone 90 
To a suspension of hexane-washed sodium hydride (34 mg, 
I.42 mmol) in THF (2 mL) was added compound 89 (341 mg, 1.41 
mmol) in THF (1 mL). The resulting solution was stirred for 
10 min at 0°C. Sorboyl chloride (184 mg, 1.41 mmol) in THF 
(1 mL) was then added dropwise, and the solution was stirred 
at 0°C for 30 min. A complex of t-BuOK/t-BuOH (528 mg, 2.84 
mmol) was then added in one portion. The reaction mixture 
was diluted with water and ether and acidified with 6 N 
hydrochloric acid to pH 6. The aqueous layer was repeatedly 
r • 
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extracted with ether. The combined extracts were washed 
with brine, dried over anhydrous magnesium sulfate, filtered 
and concentrated jji vacuo to give a brown solid, which was 
purified via flash column chromatography using 4:1 
ether:ethyl acetate as eluent to yield compound 90 (332 mg, 
70%) as an orange powder (mp 128-130®C). NMR (CDClg) 6 
14.69 (s, 1 H), 13.58 (s, 1 H), 8.39 (d, 1 H, J = 8 Hz), 
8.18 (d, 1 H, J = 8 Hz), 7.49-7.63 (m, 2 H), 7.22 (dd, 1 H, 
J = 10 and 15 Hz), 6.75 (s, 1 H), 6.06-6.26 (m, 3 H), 6.05 
(s, 1 H), 5.91 (d, 1 H, J = 15 K%), 5.52 (dd, 1 H, J = 1.2 
and 17 Hz), 5.35 (dd, 1 H, J = 1.1 and 11 Hz), 4.64 (bd, 2 
H, J = 5 Hz), 1.86 (d, 3 H, J = 6 Hz). IR (film) 3300, 
3020, 2965, 1620, 1532, 1470, 1420, 1250, 920 cm"^. Mass 
spectrum m/e 336, 295, 226, 185, 129, 95, 67. High 
resolution mass spectrum for ^21^20^4 requires 336.13616; 
measured 336.13613. C-13 NMR (CDCI3) 5 194.73, 174.54, 
157.33, 146.46, 140.29, 138.89, 133.42, 130.61, 129.33, 
126.44, 126.31, 124.13, 123.46, 121.91, 117.47, 111.10, 
101.36, 96.67, 69.56, 18.89. 
Acetate 92 
To a stirred solution of compound 89 (100 mg, 0.41 mmol) 
in acetic acid (2 mL) was added acetic anhydride (4 mL) in a 
culture tube. The reaction mixture was deoxygenated and 
heated to 200°C for 1 h. The reaction mixture was cooled to 
room temperature and diluted with ether (60 mL). The 
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organic layer was extracted with 0.2 N potassium hydroxide 
twice, washed with water and brine, dried over anhydrous 
magnesium sulfate, filtered and concentrated io vacuo to 
give a yellow solid. The crude product was purified via 
flash column chromatography using 4:1 hexanes:ethyl acetate 
as eluent to afford compound 92 (120 mg, 90%) as a white 
solid (mp 115-118°C). NMR (CDCI3) 6 7.67-7.73 (m, 2 H), 
7.46-7.56 (m, 2 H), 5.76-5.91 (m, 1 H), 4.99-5.08 (m, 2 H), 
3.43 (bd, 2 H, J = 6 Hz), 2.52 (s, 3 H), 2.43 (s, 3 H), 2.39 
(s, 3 H). IR (film) 3025, 2960, 1765, 1685, 1480, 1180, 960 
cm'^. Mass spectrum m/e 326, 284, 242, 224, 181, 152, 105, 
51. High resolution mass spectrum for C^gH^gOg requires 
326.11543; measured 326.11508. C-13 NMR (CDCI3) 6 202.20, 
169.01, 168.65, 143.32, 143.29, 141.00, 134.84, 132.55, 
127.98, 127.90, 127.16, 126.33, 124.81, 121.98, 121.72, 
116.92, 32.28, 31.61, 20.61. 
Ether 93 
To a stirred solution of compound 81 (1.0 g, 4.1 mmol) 
in acetone (15 mL) was added methyl iodide (1.8 g, 12.6 
mmol) and anhydrous potassium carbonate (1.2 g, 8.7 mmol). 
The reaction mixture was refluxed for 7 h and then diluted 
with water (50 mL). The aqueous layer was repeatedly 
extracted with methylene chloride. The combined extracts 
were washed with water and brine, dried over anhydrous 
magnesium sulfate, filtered and concentrated jjQ_ vacuo to 
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give a brown oil. The crude product was purified via flash 
column chromatography using 5:1 hexanes:ethyl acetate as 
eluent to yield compound 93 (1.0 g, 95%) as a yellow oil. 
NMR (CDCI3) 6 8.28-8.36 (m, 1 H), 8.13-8.19 (m, 1 H), 
7.53-7.63 (m, 2 H), 7.09 (s, 1 H), 6.10-6.23 (m, 1 H), 5.52 
(qd, 1 H, J = 1.5 and 17 Hz), 5.34 (qd, 1 H, J = 1.5 and 11 
Hz), 4.73 (bd, 2 H, J = 5 Hz), 3.96 (s, 3 H), 2.79 (s, 3 H). 
IR (neat) 3060, 2980, 2920, 1660, 1578, 1450, 1405, 1370, 
1215, 1090 cm~^. Mass spectrum m/e 256, 244, 215, 201, 183, 
173, 155, 127, 101, 51. High resolution mass spectrum for 
^16^16^3 256.10995; measured 256.10972. C-13 NMR 
(CDCI3) 5 199.50, 151.83, 150.50, 132.97, 129.13, 128.70, 
127.69, 127.03, 126.99, 123.15, 122.56, 117.47, 103.27, 
69.04, 63.73, 30.86. 
Ketone 94 
A solution of ether 93 (1.0 g, 3.9 mmol) in benzene (40 
mL) was deoxygenated in a culture tube. It was heated at 
210°C for 12 h. The reaction mixture was cooled, 
concentrated in. vacuo, and purified by flash column 
chromatography to afford compound 94 (0.95 g, 95%) as a 
yellow oil. NMR (CDCI3) 6 8.14-8.22 (m, 1 H), 8.01-8.07 (m, 
1 H), 7.50-7.57 (m, 2 H), 5.95-6.09 (m, 1 H), 5.49 (bs, 1 
H), 5.15-5.24 (m, 2 H), 3.87 (s, 3 H), 3.45 (td, 2 H, J = 
1.7 and 6 Hz), 2.61 (s, 3 H). IR (neat) 3475, 3060, 2920, 
1680, 1580, 1445, 1417, 1366, 1212, 1193, 1070, 990 cm"^. 
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Mass spectrum m/e 256, 241, 226, 210, 198, 181, 165, 152, 
115, 77, 51. High resolution mass spectrum for C^gH^gO^ 
requires 256.10995; measured 256.10998. C-13 NMR (CDClg) 5 
205.83, 146.82, 146.39, 135.49, 132.71, 127.21, 126.56, 
126.14, 122.07, 121.99, 116.95, 114.07, 63.76, 33.01, 31.54. 
General procedure for the reductive methylation 
To a mixture of quinone (2 mmol) and tetrabutylammonium 
bromide (75 mg) in THF (5 mL) and water (2 mL) was added 
aqueous sodium dithionate (12 mmol). After 15 min at 
ambient temperature, aqueous potassium hydroxide (46 mmol) 
was added. After 5 min, dimethyl sulfate (4 mL) was added 
and the mixture was stirred for 10 h. The product was 
isolated by partitioning between water and methylene 
chloride. The crude product was purified by silica gel 
chromatography. 
Ether 95: NMR (CDCI3) 6 6.28 (bs, 2 H), 3.80 (s, 3 H), 
3.75 (s, 6 H), 2.24 (s, 3 H). IR (film) 1605, 1500, 1336, 
1220, 826, 764 cm"^. Mass spectrum m/e 182, 167, 139, 124, 
107. High resolution mass spectrum for C^gH^^Og requires 
182.0943; measured 182.0943. C-13 NMR (CDCI3) 6 155.78, 
155.23, 141.47, 131.94, 106.04, 97.86, 60.16, 55.66, 55.39, 
16.01. 
Ether 96; NMR (CDCI3) 6 8.05-8.30 (m, 2 H), 6.61 (s, 2 
H), 3.92 (s, 6 H). IR (film) 3060, 2930, 1580, 1438, 1380, 
1221, 1072 cm ^. Mass spectrum m/e 188, 173, 145, 130, 115, 
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102/ 91, 76. High resolution mass spectrum for 
requires 188.0837; measured 188.0835. C-13 NMR (CDClg) g 
149.599, 126.412, 125.817, 121.808, 103.280, 55.716. 
Ether 97; NMR (CDCI3) g 7.90-8.30 (m, 2 H), 7.15-7.70 
(m, 2 H), 6.56 (s, 1 H), 3.97 (s, 3 H), 3.94 (s, 3 H), 3.90 
(s, 3 H). IR (film) 1620, 1590, 1445, 1360, 1205, 998, 760 
cm~^. Mass spectrum m/e 218, 203, 175, 160, 102. High 
resolution mass spectrum for requires 218.0943; 
measured 218.0944. C-13 NMR (CDCI3) g 152.42, 148.14, 
136.87, 129.34, 126.74, 123.27, 121.97, 121.48, 120.89, 
95.59, 61.03, 57.23, 55.55. 
Ether 98: NMR (CDCI3) g 8.02-8.10 (m, 2 H), 7.42-7.58 
(m, 2 H), 3.96 (s, 3 H), 3.86 (s, 3 H), 2.52 (s, 3 H). IR 
(film) 1580, 1459, 1358, 1000, 750 cm"^. Mass spectrum m/e 
282, 280, 267, 265, 171, 143, 115, 69. High resolution mass 
spectrum for C^gH^gOgBr requires 280.00949; measured 
280.00989. C-13 NMR (CDCI3) g 150.57, 149.92, 127.93, 
127.66, 127.33, 126.52, 126.20, 122.46, 117.26, 61.62, 
61.30, 16.66. 
Ether 99; NMR (CDCI3) g 8.01-8.21 (m, 2 H), 7.44-7.59 
(m, 2 H), 6.83 (s, 1 H), 3.96 (s, 3 H), 3.85 (s, 3 H). IR 
(film) 3060, 2912, 1618, 1570, 1452, 1355, 1210, 1100 cm"^. 
Mass spectrum m/e 268, 266, 253, 251, 225, 223, 188, 157, 
129, 101, 75. High resolution mass spectrum for 
requires 265.99424; measured 265.99426. C-13 NMR (CDCI3) g 
[ 
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152.28, 146.79, 129.02, 127.37, 127.28, 125.80, 122.61, 
121.84, 111.90, 107.96, 61.43, 55.93. 
Ether IjQjO: NMR (CDCI3) 6 8.05-8.34 (m, 4 H), 7.22-7.54 
(m, 4 H), 4.07 (s, 6 H). IR (film) 3042, 2910, 1621, 1568, 
1360, 1220, 1100, 980 cm"^. Mass spectrum m/e 238, 223, 
208, 180, 152, 136, 109, 87, 59. High resolution mass 
spectrum for C2^gHj^^02 requires 238.0994; measured 238.0996. 
C-13 NMR (CDCI3) 6 148.57, 125.38, 125.00, 122.62, 63.19. 
Ether 101; NMR (CDCI3) 5 8.20-8.50 (m, 2 H), 7.26-7.68 
(m, 2 H), 6.58 (s, 2 H), 3.98 (s, 12 H). IR (film) 1620, 
1450, 1355, 1252, 1080 cm~^. Mass spectrum m/e 298, 283, 
252, 225, 149. High resolution mass spectrum for C^gH^gO^ 
requires 298.1205; measured 298.1208. C-13 NMR (CDClg) 6 
150.52, 148.90, 126.85, 125.93, 122.95, 119.86, 104.20, 
63.46, 56.91. 
Ether 102; NMR (CDCI3) 6 8.18-8.40 (m, 2 H), 8.05 (d, 1 
H, J = 2 Hz), 7.43-7.55 (m, 2 H), 6.81 (d, 1 H, J = 2 Hz), 
4.05 (s, 6 H), 3.98 (s, 3 H). IR (film) 1590, 1300, 1055, 
755 cm"^. Mass spectrum m/e 348, 346, 333, 331, 209, 151. 
High resolution mass spectrum for Ci^H^gOgBr requires 
346.0204; measured 346.0205. C-13 NMR (CDCI3) 6 157.24, 
149.60, 147.16, 128.85, 127.71, 127.12, 126.52, 125.93, 
125.60, 123.43, 122.08, 119.37, 117.04, 107.61, 63.57, 
62.97, 56.37. 
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Ether lg3: NMR (CDCI3) 6 7.81 (d, 2 H, J = 8 Hz), 
7.16-7.46 (m, 2 H), 6.68 (d, 2 H, J = 7 Hz), 4.02 (s, 9 H), 
3.88 (s, 3 H). IR (film) 3020, 2920, 1640, 1462, 1350, 
1251, 1080 cm ^. Mass spectrum m/e 298, 283, 268, 253. 
High resolution mass spectrum for C^gH^gO^ requires 
298.1205; measured 298.1207. C-13 NMR (CDCI3) 6 157.51, 
150.95, 147.43, 127.55, 125.76, 119.10, 114.66, 104.31, 
63.62, 62.43, 56.31. 
Phenol 109a 
To a well stirred suspension of 1,5-dihydroxynaphthalene 
(20.0 g, 120 mmol) in glacial acetic acid (500 mL) at 80® 
was added bromine (13 mL, 240 mmol) in acetic acid (50 mL) 
slowly. After addition, the reaction mixture was stirred 
for 15 min. On standing at room temperature, the green 
needles were separated. Recrystallization of this substance 
from acetic acid afforded 109a (30.9 g, 81%) as pale green 
crystals (mp 223-225°C). NMR (CDCI3) 5 8.55 (s, 2 H), 7.73 
(d, 2 H, J = 9 Hz), 7.56 (d, 2 H, J = 9 Hz. IR (film) 3400, 
3060, 1620, 1570, 1375, 1220, 1105, 975 cm"^. Mass spectrum 
m/e 320, 318, 316, 241, 239, 211, 209, 129, 102, 75. High 
resolution mass spectrum for C^gHgOgBrg requires 315.87345; 
measured 315.87350. C-13 NMR (Dg-acetone) 6 150.68, 130.87, 
127.28, 116.73, 106.39. 
85 
Phenol 109b 
To a stirred solution of compound 109a (10.0 g, 31.4 
mmol) and sodium hydroxide (3.8 g, 94.3 mmol) in water (60 
mL) was added dimethyl sulfate (7.8 g, 62.0 mmol). The 
reaction mixture was stirred for 2 h at room temperature and 
filtered. The alkaline filtrate was acidified with 6 N 
hydrochloric acid and a white precipitate was separated. 
Recrystallization of this precipitate from alcohol afforded 
109b (5.2 g, 50%) as colorless needles (mp 148-150*C). NMR 
(CDCI3) 6 7.88 (d, 1 H, J = 9 Hz), 7.59 (d, 2 H, J = 9 Hz), 
7.52 (d, 1 H, J = 9 Hz), 5.99 (s, 1 H), 3.98 (s, 3 H). IR 
(film) 3350, 3040, 1530, 1140, 965 cm ^. Mass spectrum m/e 
334, 332, 330, 319, 317, 315, 291, 289, 287, 178, 129, 100, 
74. High resolution mass spectrum for C^^HgOgBrg requires 
329.88910; measured 329.88933. C-13 NMR (CDCI3) 6 153.09, 
148.59, 130.53, 129.64, 129.42, 124.91, 119.80, 115.66, 
114.10, 104.98, 61.56. 
Quinone 61 
To a well stirred suspension of compound 109b (0.5 g, 
1.5 mmol) in glacial acetic acid (5 mL) at 0°C was added 
chromium trioxide (1.1 g, 11.0 mmol) in water (3 mL). The 
reaction mixture was allowed to stir at room temperature for 
6 h, diluted with water (20 mL), and filtered through sinter 
glass funnel. The yellow precipitate was washed thoroughly 
with distilled water and dried under vacuum. 
86 
Recrystalllzatlon of the precipitate from aqueous alcohol 
afforded qulnone 61 (325 mg, 63%) as bright yellow needles 
(mp 174-176»C). NMR (CDCI3) 6 7.97 (d, 1 H, J = 8 Hz), 7.87 
(d, 1 H, J = 8 Hz), 7.44 (s, 1 H), 3.94 (s, 3 H). IR (film) 
3035, 2962, 1665, 1325, 1120 cm"^. Mass spectrum m/e 348, 
346, 344, 330, 328, 326, 317, 267, 265, 237, 209, 87, 53. 
High resolution mass spectrum for C22Hg02Br2 requires 
343.86836; measured 343.86845. C-13 NMR (CDCI3) 6 180.43, 
177.23, 156.97, 141.46, 138.45, 137.80, 131.77, 128.23, 
125.04, 124.92, 61.70. 
Quinone 110 
To diisopropylamine (0.06 mL, 0.38 mmol) in dry THF (3 
mL) at -78°C under nitrogen was added n-BuLi (0.13 mL, 0.32 
mmol) dropwise. The solution was stirred for 15 min and a 
solution of anhydride 60 (46.8 mg, 0.29 mmol) in THF (1 mL) 
was added dropwise. After addition, the reaction mixture 
was stirred for 5 min and a solution of quinone 110 (100 mg, 
0.29 mmol) in THF (1 mL) was added. The resulting mixture 
was allowed to warm to room temperature and stirred for 4 h. 
The reaction mixture was then added water (5 mL), acidified 
with 6 N hydrochloric acid and extracted repeatedly with 
chloroform. The combined extracts were washed with water 
and brine, dried over anhydrous magnesium sulfate, filtered 
and concentrated ifl vacuo. The crude product was 
recrystallized from acetone (2 mL) to give compound 110 
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(78.0 mg, 70%) as orange solid (mp 257-259*0). NMR (CDClg) 
g 14.28 (s, 1 H), 8.44 (d, 1 H, J = 8 Hz), 8.19 (a, 1 H), 
8.05 (d, 1 H, J = 8 Hz), 7.95 (d, 1 H, J = 8 Hz), 7.92 (d, 1 
H, J = 8 Hz), 7.59-7.71 (m, 2 H), 4.04 (s, 3 H). IR (film) 
3360, 3020, 2965, 1665, 1320, 1140 cm~^. Mass spectrum m/e 
384, 382, 274, 257, 189, 95. High resolution mass spectrum 
for CjgHj^j^O^Br requires 381.98407; measured 381.98331. C-13 
NMR (CDCI3) 6 186.61, 163.48, 157.91, 136.63, 135.43, 
131.42, 130.38, 129.41, 128.92, 128.15, 127.41, 124.84, 
124.31, 121.92, 121.82, 115.61, 111.88, 109.09, 61.82. 
Napthacene (59) 
To a mixture of quinone 110 (100 mg, 0.26 mmol) and 
tetrabutylammonium bromide (20 mg) in THF (5 mL) and water 
(2 mL) was added aqueous sodium dithionate (455 mg, 2.6 
mmol). After 15 min at ambient temperature, aqueous 
potassium hydroxide 756 mg, 13.5 mmol) was added. After 2 
min, dimethyl sulfate (4 mL) was added and the mixture was 
stirred for 10 h. The product was isolated by partitioning 
between water and methylene chloride. The crude product was 
purified by silica gel chromatography to afford compound 59 
(56 mg, 51%). NMR (CDCI3) 5 8.89 (s, 1 H), 8.60 (d, 1 H, J 
= 8 Hz), 8.00-8.09 (m, 2 H), 7.38-7.58 (m, 3 H), 4.13 (s, 3 
H), 4.12 (s, 3 H), 4.08 (s, 3 H), 4.01 (s, 3 H). IR (film) 
3025, 2912, 1610, 1572, 1320, 1240, 1105 cm"^. High 
resolution mass spectrum for Cg^HigO^Br requires 426.04667; 
measured 426.04648. C-13 NMR (CDCI3) 5 157.30, 151.40, 
149.60, 147.26, 128.76, 128.52, 127.81, 127.36, 127.10, 
126.59, 125.90, 125.48, 123.50, 122.42, 120.35, 119.92, 
117.18, 109.30, 63.49, 62.56, 57.48, 56.93. 
Alcohol 112 
To a stirred solution of compound 111 (2.83 g, 11.24 
mmol) in THF (25 mL) and ether (15 mL) at -78*C under 
nitrogen atmosphere was added n-butyllithium (4.5 mL, 11.24 
mmol) dropwise. The reaction mixture was stirred for 30 min 
at -78°C. Ketone 85 (3.90 g, 8.65 mmol) in THF (5 mL) was 
added slowly. After addition, the solution was warmed 
slowly to 0°C and stirred for 15 min. The resulting mixture 
was quenched with 2 N ammonium chloride (30 mL) and 
extracted repeatedly with dichloromethane. The combined 
extracts were washed with brine, dried over anhydrous 
magnesium sulfate, filtered and concentrated in vacuo to 
give a yellow residue, which was purified via flash column 
chromatography using 4:1 hexanes:ethyl acetate as eluent to 
afford compound 112 (3.25 g, 60%) as a viscous liquid. NMR 
(CDCI3) 6 7.38 (s, 1 H), 6.86 (bs, 1 H), 4.45-4.85 (m, 5 H), 
4.10-4.23 (m, 3 H), 3.87 (s, 3 H), 3.78 (s, 3 H), 3.60-3.77 
(m, 2 H), 3.36 (s, 3 H), 3.33 (s, 2 H), 2.99 (s, 3 H), 1.61 
(s, 3 H), 1.25 (t, 3 H, J = 7 Hz), 0.88 (s, 9 H), 0.06 (s, 3 
H), 0.04 (s, 3 H). IR (neat) 3450, 2930, 1665, 1485, 1370, 
1250, 1200, 830 cm ^. High resolution mass spectrum for 
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^28^50^10^^^'^^ requires 623.2884; measured 623.2892. C-13 
NMR (CDCI3) 5 157.60, 157.49, 153.52, 151.43, 147.25, 
130.43, 125.42, 115.29, 113.48, 97.48, 96.21, 89.42, 88.65, 
84.76, 79.50, 75.66, 75.42, 65.07, 63.87, 62.95, 56.79, 
55.19, 55.08, 31.56, 31.20, 26.79, 26.03, 17.80, 17.12, 
14.45, 14.30, -5.71, -5.61. 
Alcohol 113 
To a stirred solution of compound 112 (2.82 g, 4.53 
mmol) in THF (9 mL) at room temperature was added 
tetrabutylammonium fluoride (4.53 mL, 4.53 mmol). After 
stirring for 3 h, 2 N ammonium chloride (10 mL) was added 
and the resulting mixture was repeatedly extracted with 
dichloromethane. The combined extracts were washed with 
brine, dried over anhydrous magnesium sulfate, filtered and 
concentrated in vacuo to give an oil, which was purified via 
flash column chromatography using 1:1 hexanes;ethyl acetate 
as eluent to afford compound 113 (2.23 g, 97%) as a 
colorless oil. NMR (CDCI3) 6 7.12 (s, 1 H), 7.00 (bs, 1 H), 
4.95-5.21 (m, 2 H), 4.51-4.80 (m, 4 H), 4.17 (bq, 2 H, J = 7 
Hz), 3.90 (s, 3 H), 3.82 (m, 2 H), 3.79 (s, 3 H), 3.38 (s, 3 
H), 3.32 (m, 1 H), 3.25 (bs, 3 H), 3.00 (s, 3 H), 1.92 (bs, 
3 H), 1.29 (bt, 3 H, J = 7 Hz). IR (neat) 3450, 3022, 2940, 
1680, 1490, 1400, 1370, 1262, 1210, 915 cm"^. High 
resolution mass spectrum for CggHggO^QClN requires 
509.20188; measured 509.20176. C-13 NMR (CDCI3) 6 157.69, 
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157.38, 153.50, 151.49, 131.27, 128.60, 127.69, 124.05, 
119.87, 99.87, 99.10, 97.36, 95.60, 89.30, 88.73, 77.71, 
76.05, 73.01, 72.56, 67.21, 65.40, 63.23, 62.51, 60.75, 
55.61, 55.43, 55.10, 54.62, 31.18, 30.92, 26.71, 26.42, 
24.18, 14.45. 
Lactone 114 
To a well stirred solution of dry pyridine (10 mL, 100 
mmol) in dichloromethane (100 mL) at 0*C was added chromium 
trioxide (5.0 g, 50 mmol) in portions under nitrogen 
atmosphere. Stirring was continued for 10 min at room 
temperature after complete addition. Compound 113 (2.5 g, 
5.1 mmol) was added to the freshly prepared Collins reagent 
solution and the reaction mixture was stirred for 1 h. The 
dark mixture was passed through a column containing silica 
gel with ethyl acetate as solvent and the combined solution 
was concentrated in vacuo. The resulting crude product was 
purified via flash column chromatography using 2:1 
hexanes;ethyl acetate as eluent to yield compound 114 (2.1 
g, 81%) as a viscous liquid. NMR (CDClg) 5 7.02 (s, 1 H), 
6.95 (s, 1 H), 4.97-5.21 (m, 2 H), 4.60-4.75 (m, 2 H), 4.55 
(m, 1 H), 4.17 (bq, 2 H, J = 7 Hz), 3.87 (s, 3 H), 3.78 (s, 
3 H), 3.38 (s, 3 H), 3.35 (m, 1 H), 3.25 (bs, 3 H), 3.01 (s, 
3 H), 1.93 (bs, 3 H), 1.27 (bt, 3 H, J = 7 Hz). IR (neat) 
2925, 1740, 1685, 1495, 1460, 1375, 1210, 1150, 1030, 905 
cm~^. High resolution mass spectrum for ^22832010^^^ 
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requires 505.17056; measured 505.17102. C-13 NMR (CDClg) S 
169.94, 155.81, 150.05, 148.43, 122.36, 113.98, 113.63, 
112.23, 96.92, 96.59, 84.79, 79.50, 75.77, 70.09, 63.99, 
62.05, 56.72, 56.19, 55.77, 34.82, 27.75, 14.50. 
Quinone 115 
To a solution of eerie ammonium nitrate (3.3 g, 6.0 
mmol) in water (4 mL) and acetonitrile (2 mL) at 0°C was 
added compound 114 (500 mg, 1.0 mmol) in acetonitrile (5 mL) 
and potassium acetate (394 mg, 4.0 mmol). After addition, 
the reaction mixture was allowed to warm to room temperature 
and stirred for 1 h. The resulting mixture was repeatedly 
extracted with dichloromethane. The combined extracts were 
washed with brine, dried over anhydrous magnesium sulfate, 
filtered and concentrated in vacuo to give crude product 
115^(432 mg, 91%) as an orange substance. NMR (CDCI3) 6 
7.13 (s, 1 H), 6.97 (s, 1 H), 5.45 (d, 1 H, J = 7 Hz), 5.19 
(m, 1 H), 4.72 (d, 1 H, J = 7 Hz), 4.68 (m, 1 H), 4.21 (bq, 
2 H, J = 7 Hz), 3.34 (m, 1 H), 3.38 (s, 3 H), 3.27 (s, 3 H), 
1.89 (bs, 3 H), 1.31 (t, 3 H, J = 7 Hz). IR (film) 2920, 
2840, 1750, 1670, 1660, 1475, 1370, 1020, 915 cm"^. High 
resolution mass spectrum for C^QHggO^gClN requires 
475.12358; measured 475.12381. C-13 NMR (CDCI3) S 181.43, 
177.65, 170.90, 156.77, 153.59, 140.59, 137.45, 136.90, 
98.70, 96.33, 76.24, 69.50, 68.78, 65.41, 60.20, 57.23, 
56.42, 38.50, 27.89, 14.30. 
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Alcohol 116 
To a stirred solution of compound 59 (100 mg, 0.23 mmol) 
in THF (1 mL) at -78*C under nitrogen atmosphere was added 
n-butyllithium (0.10 mL, 0.23 mmol) dropwise. The reaction 
mixture was stirred for 30 min at -78*C. Ketone 85 (104 mg, 
0.23 mmol) in THF (1 mL) was added slowly. After addition, 
the solution was warmed slowly to 0®C and stirred for 15 
min. The resulting mixture was quenched with 2 N ammonium 
chloride (10 mL) and extracted repeatedly with 
dichloromethane. The combined extracts were washed with 
brine, dried over anhydrous magnesium sulfate, filtered and 
concentrated ia vacuo to give an orange residue, which was 
purified via flash column chromatography using 4:1 
hexanes:ethyl acetate as eluent to afford compound 116 (96 
mg, 52%) as an orange liquid. NMR (CDClg) 6 8.18-8.25 (m, 3 
H), 7.43-7.^62 (m, 4 H), 4.56-4.89 (m, 4 H), 4.04-4.21 (m, 6 
H), 4.00, 3.99 and 3.97 (s, 12 H), 3.36, 3.31 and 3.29 (s, 6 
H), 3.01 and 2.98 (s, 3 H), 1.79 (s, 3 H), 1.10-1.31 (m, 3 
H), 0.90 and 0.88 (s, 9 H), 0.04 and 0.03 (s, 6 H). IR 
(film) 3440, 3020, 2975, 1670, 1435, 1220, 1160, 916 cm"^. 
Mass spectrum m/e 799 (M*), 761, 629, 601, 432, 351, 173. 
Alcohol 117 
To a stirred solution of compound 116 (65 mg, 0.08 mmol) 
in THF (1 mL) at room temperature was added 
tetrabutylammonium fluoride (0.08 mL, 0.08 mmol). After 
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stirring for 3 h at room temperature, 2 N ammonium chloride 
(5 mL) was added and the resulting mixture was repeatedly 
extracted with dichloromethane. The combined extracts were 
washed with brine, dried over anhydrous magnesium sulfate, 
filtered and concentrated in. vacuo to give an orange 
residue, which was purified via flash column chromatography 
using 2:1 hexanes:ethyl acetate as eluent to afford compound 
117 (53 mg, 97%) as an orange oil. NMR (CDCl^) 6 8.25 (d, 1 
H, J = 8 Hz), 7.98 (d, 1 H, J = 8 Hz), 7.41-7.58 (m, 5 H), 
4.21-4.80 (m, 6 H), 4.02-4.09 (m, 2 H), 4.01, 4.00, 3.98, 
3.96 (s, 12 H), 3.32 (s, 3 H), 3.26 (s, 3 H), 2.96, 2.94 (s, 
3 H), 1.79 (s, 3 H), 1.22 (t, 3 H, J = 7 Hz). IR (neat) 
3450, 3020, 2975, 1665, 1220, 1150, 945 cm"^. Mass spectrum 
m/e 685 (M+), 660, 547, 479, 243. 
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